

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 919 621 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
02.06.1999 Bulletin 1999/22

(51) Int. Cl.<sup>6</sup>: **C12N 15/54**, C12P 21/02,  
C12N 9/12, C12N 1/21

(21) Application number: **97908525.5**

(86) International application number:  
**PCT/JP97/01050**

(22) Date of filing: **27.03.1997**

(87) International publication number:  
**WO 98/03663 (29.01.1998 Gazette 1998/04)**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(30) Priority: **24.07.1996 US 685625**  
**27.09.1996 JP 256747/96**

(71) Applicant:  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
**Tokyo 115 (JP)**

(72) Inventors:  
• **MATSUMOTO, Kunihiro**  
**Nagoya-shi, Aichi 464 (JP)**  
• **IRIE, Kenji**  
**Nagoya-shi, Aichi 466 (JP)**

(74) Representative: **HOFFMANN - EITLE**  
**Patent- und Rechtsanwälte**  
**Arabellastrasse 4**  
**81925 München (DE)**

(54) **HUMAN TAKI DNA ENCODING THE SAME**

(57) A TGF- $\beta$ -activated kinase comprising an amino acid sequence from Met at position 1 to Ser at position 579 in the amino acid sequence as set forth set forth in SEQ ID NO: 5, and DNA encoding the kinase.

**EP 0 919 621 A1**

## Description

## Technical Field

5 [0001] The present invention relates to a kinase (transforming growth factor- $\beta$  (TGF- $\beta$ ) activated kinase 1; TAK1) carrying the signal transduction system of the TGF- $\beta$  family, said kinase being activated by TGF- $\beta$ , a method for producing the kinase, and a human gene encoding the kinase. TAK1, also referred to as the activator of MAPK kinase (AMK-1), is an enzyme that is activated by TGF- $\beta$  and BMP (bone morphogenetic protein) and that phosphorylates and thereby

## Background Art

10 [0002] Receptors of the TGF- $\beta$  superfamily contain Ser/Thr kinase in the intracellular domain and are divided into type I that has a repeated sequence of Gly and Ser (GS box) at the amino-terminal end near the transmembrane domain and type II that does not have the GS box. It is believed, in the case of TGF- $\beta$ , that it forms a complex with the type I receptor after a ligand has bound to the type II receptor, in which a constitutively phosphorylated kinase of the type II receptor phosphorylates the vicinity of GS box of the type I receptor, thereby activating the type I receptor so that a signal from the above ligand is transmitted into the cell. However, little is known about signaling molecules downstream of this receptor.

20 [0003] For a eukaryotic budding yeast *Saccharomyces cerevisiae*, it is known, as a signal transduction cascade in which an extracellular mating pheromone causes conjugation, that the mating pheromone activates a G-protein, which in turn activates a MAPKK kinase (MAPKKK) (Ste11), and the activated MAPKKK phosphorylates and activates a MAPK kinase (MAPKK), and then the thus activated MAPKK (Ste7) phosphorylates and activates a MAP kinase (mitogen-activated protein kinase; MAPK), and finally the MAPK activates FUS1 protein to initiate cell conjugation.

25 [0004] As such a MAPKKK, TAK1 (TGF- $\beta$  activated kinase 1) derived from mouse has been known so far (K. Yamaguchi et al., Science (1995) 270, 2008-2011).

## Disclosure of Invention

30 [0005] The present invention intends to provide a novel factor in the signaling system of the receptor of mammalian TGF- $\beta$  said factor being located downstream of said receptor and being involved in said signaling system; gene encoding said factor; and a method for producing said factor.

[0006] In efforts to solve the above problems, the applicants of the present invention have succeeded in inserting a human-derived cDNA into a yeast *Saccharomyces cerevisiae* that is deficient in MAPKKK activity (Ssk2/Ssk22, Sho1) in the signal transduction cascade of the above mating pheromone, screening for cDNAs that can complement the activity-deficient MAPKKK, and cloning cDNAs that can complement the activity-deficient MAPKKK, and thereby have accomplished the present invention.

[0007] Thus, the present invention provides a polypeptide having a kinase activity that is activated by transforming growth factor (TGF)- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.

[0008] The present invention also provides a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5.

[0009] The present invention also provides DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.

[0010] The present invention also provides DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said DNA comprising a nucleic acid sequence from T at position 249 to A at position 1919 set forth in SEQ ID NO: 5.

[0011] The present invention also provides DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5.

[0012] The present invention also provides DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said DNA comprising a nucleic acid sequence from A at position 183 to A at position 1919 set forth in SEQ ID NO: 5.

55 [0013] The present invention also provides a vector comprising any of the above-mentioned DNAs, a host cell transformed with a vector comprising any of the above-mentioned DNAs, and a method for producing a polypeptide having a kinase activity that is activated by TGF- $\beta$ , which method comprises culturing a host cell transformed with a vector comprising any of the above-mentioned DNAs and then recovering a product from the culture.

[0014] The present invention also provides a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide being produced by the above method, and a kinase that is activated by TGF- $\beta$ , said kinase comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.

[0015] The present invention also provides a fusion protein of the above polypeptide, protein and another protein.

#### Brief Explanation of the Drawings

#### [0016]

Fig. 1 shows a yeast expression vector pNV11.

Fig. 2 is a graph showing the effects of TGF- $\beta$  addition on the expression of various TAK1 genes evaluated using a luciferase gene as a reporter gene.

Fig. 3 is a graph showing the effects of TGF- $\beta$  and BMP-4 on the activity of a TAK1 gene in MC3T3-E1 cells as measured by an immunoprecipitation method and a coupled kinase method.

Fig. 4 is a graph showing the effects of various concentrations of TGF- $\beta$  or BMP-4 on TAK1 kinase activity in the cells transfected with the HA-TAK1 gene. TAK1 $\Delta$ N shows a result when the cells transfected with the TAK1 $\Delta$ N gene were not stimulated by either TGF- $\beta$  or BMP-4.

Fig. 5 shows a comparison of the base sequence of DNA encoding mouse TAK1 and that of DNA encoding human TAK1.

Fig. 6 shows a comparison of the base sequence of DNA encoding mouse TAK1 and that of DNA encoding human TAK1.

Fig. 7 shows a comparison of the base sequence of DNA encoding mouse TAK1 and that of DNA encoding human TAK1.

Fig. 8 shows a comparison of the base sequence of DNA encoding mouse TAK1 and that of DNA encoding human TAK1.

Fig. 9 shows a comparison of the base sequence of DNA encoding mouse TAK1 and that of DNA encoding human TAK1.

Fig. 10 shows a comparison of the amino acid sequence of mouse TAK1 and that of human TAK1.

Fig. 11 shows a comparison of the amino acid sequence of mouse TAK1 and that of human TAK1.

#### Embodiment for Carrying out the Invention

[0017] In accordance with the present invention, the cloning of the desired gene can be detected by inserting, for example, an expression vector comprising a mammalian cDNA into a yeast that is deficient in the MAPKKK activity and that has a readily detectable reporter gene at the terminal of the cascade, and then by expressing said reporter gene to detect the introduction of cDNA that complements the deficient MAPKKK activity. Moreover, another yeast can be used that is deficient in Ssk2/Ssk22 and Sho1 activity and that functions, for example, in a high osmotic pressure-signaling system.

[0018] As such a detection system, there can be used a MAPK route that transmits a signal of the mating pheromone in *Saccharomyces cerevisiae* (I. Herskowitz, Cell, Vol. 80, 187 (1995); D.E. Lein et al., Curr. Opin. Cell Biol. Vol. 7, 197 (1995); J. Schulz et al., Curr. Opin. Gene Dev., Vol. 5, 31 (1995)). The normal signal transduction cascade in this system consists of Ste11 kinase, Ste7 kinase, and Fus3/Kss1 kinase, which correspond to MAPKKK, MAPKK, and MAPK, respectively. Ste11, Ste7, and Fus3/Kss1 sequentially act to thereby transmit signals to the transcription factor Ste12, which Ste12 in turn activates the transcription of a mating-specific gene such as FUS1.

[0019] With respect to the screening of cDNA, there can be used a cascade that has a functional mutation of Ste7 (STE7<sup>P368</sup>) and a deficiency mutation of Ste11 (Ste11 $\Delta$ ) in the above cascade (K. Irie et al., Science Vol. 265, 1716 (1994)). In this system, it has been confirmed that a mammalian Raf or an activated type of MEKK (Faf $\Delta$ N or MEKK $\Delta$ N, respectively) complements the deficiency of Ste11 activity in a Ste7<sup>P368</sup>-dependent manner, when it is monitored by a histidine phenotype (His) imparted by the reporter gene FUS1p::HIS3 corresponding to the mating route. Thus, by introducing the subject cDNA into a yeast having the above mutated cascade and by detecting the histidine phenotype, cDNA that can complement Ste11 $\Delta$  (MAKKK deficiency) can be selected.

[0020] As the subject cDNA, there can be used a cDNA library of any mammalian origin. For example, a cDNA expression library from a mouse cell line such as the mouse cell line BAF-B03. This cDNA library can be obtained by cloning cDNA corresponding to poly (A)-RNA from a mouse IL-3-dependent pro- $\beta$  cell line BAF-B03 under the control of TDH3 promoter of a yeast expression vector pNV11. Another example of the subject cDNA library to be used is a human cell line such as a cDNA expression library from a human cell line Jurkat.

[0021] One positive clone was obtained by screening the above cDNA library using the above screening system. The base sequence of cDNA of this clone and the amino acid sequence encoded by the cDNA correspond to the nucleotide

numbers 223 to 1893 and the amino acid numbers 23 to 579 of SEQ ID NO: 1.

[0022] cDNA libraries from a human cell line can be screened by the above screening system. Alternatively, cDNA libraries from a human cell line can be screened using a mouse cDNA as a probe in the manner described above.

[0023] The cDNA of another positive clone and the amino acid sequence encoded by the cDNA correspond to the nucleotides 249 to 1919 and the amino acids 23 to 579 set forth in SEQ ID NO: 5.

[0024] In order to obtain a longer cDNA (full-length cDNA), the above cDNA libraries were screened using said cDNA as a probe to thereby obtain multiple positive clones. These clones had a 5'-extension of approximately 230 bp to said cDNA. cDNA that contains this 5'-extension was designated as TAK1 cDNA and cDNA that was cloned first and that does not contain this 5'-extension was designated as TAK1 $\Delta$ N cDNA. The nucleotide sequence of TAK1 cDNA is shown in 1 to 2443 of SEQ ID NO: 1, and the amino acid sequence encoded by the cDNA is shown in the amino acid numbers 1 to 579 of SEQ ID NO: 1. The protein or the polypeptide represented by the amino acid sequence is designated as TAK1 protein or polypeptide. In contrast, the protein or the polypeptide represented by the amino acid sequence encoded by TAK1  $\Delta$ N cDNA is designated as TAK1  $\Delta$ N protein or polypeptide. Furthermore, the nucleotide sequence of human TAK1 cDNA is represented by the nucleotides 1 to 2656 and the amino acid sequence encoded by it is represented by the amino acids 1 to 579 of SEQ ID NO: 5.

[0025] The primary sequence of the TAK1 protein suggests that this protein has a protein kinase catalysis domain at the N-terminal end and a C-terminal domain of about 300 amino acid residues. This catalysis domain contains a consensus sequence corresponding to the protein kinase subdomains I to XI (S.K. Hanks et al., Science 241, 42 (1988)). This catalysis domain has an about 30% identity with the amino acid in the Raf-1 (T.I. Bonner et al., Nucleic Acids Res. Vol. 14, 1009 (1986)) and MEKK (C.A. Langer-Carter et al., Science Vol. 260, 315 (1993)). The sequence of the 300 amino acid residues at the C-terminal following the above catalysis domain does not have a conspicuous homology with other proteins.

[0026] TAK1  $\Delta$ N cDNA deficient in the codons of 22 amino acids at the N-terminal which has been introduced into a yeast having a ste11 $\Delta$  mutation can complement the ste11 $\Delta$  mutation (MAPKKK deficiency), but the full-length TAK1 cDNA introduced into a ste11  $\Delta$  mutant does not complement the ste11 $\Delta$  mutation. It is believed, therefore, that TAK1 kinase is activated by the removal of 22 the amino acids in the N-terminal.

[0027] Thus, the present invention provides DNA encoding a polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5. This DNA includes, as a typical example, DNA encoding a polypeptide comprising an amino acid sequence from the amino acid Ser at position 23 to the amino acid Ser at position 579, and DNA encoding a polypeptide comprising an amino acid sequence from an amino acid Glu at position 30 to an amino acid Asp at position 295. However, the DNA of the present invention is not limited to the above DNAs and may also include DNA encoding a polypeptide comprising an amino acid sequence from any of the amino acids from Met at position 1 to Glu at position 30 to the amino acid Asp at position 295.

[0028] Because it is believed that even from DNA encoding a polypeptide having an extended N-terminal, an active enzyme could be obtained by processing of the polypeptide after expression, and that it will have a similar kinase activity even without regions other than the kinase at the C-terminal.

[0029] The present invention also provides polypeptides or proteins, especially polypeptides or proteins retaining the TAK1 activity, having the amino acid sequences corresponding to the nucleotide sequences of various DNAs mentioned above. As a more specific example, the present invention relates to polypeptides or proteins expressed by introducing various DNAs mentioned above as they are inserted into, for example a vector, especially an expression vector, into host cells such as animal cells or microorganism cells.

[0030] Typically, the polypeptide or the protein of the present invention has an amino acid sequence from any of an amino acid from Met at position 1 (inclusive) to Ser at position 23 (inclusive) to the amino acid Ser at position 579 of SEQ ID NO: 5.

[0031] The present invention also provides a fusion protein of the above polypeptide or protein and another protein. Another protein that is fused with a polypeptide or a protein having the TAK1 activity may be chosen as appropriate in addition to hemagglutinin mentioned in examples. DNA encoding a fusion protein of a polypeptide or a protein having the TAK1 activity with another protein can be constructed and expressed by the method set forth in Example 4.

[0032] As mentioned earlier, cDNA encoding human TAK1 can be obtained using cDNA encoding mouse TAK1; Examples 5 and 6 describe the isolation of cDNA encoding human TAK1.

[0033] The various DNAs of the present invention mentioned above can be cloned from an animal cell as, for example, cDNA by the method set forth in Example 2. Mutated or modified DNA as compared to the original cDNA can be prepared using the original cDNA as a template in a conventional method such as PCR amplification and site-specific mutagenesis.

[0034] The polypeptides or proteins of the present invention can be obtained by expressing the corresponding DNA in a suitable host cell. As the host cell in this case, there may be used cultured cells of higher eukaryotic cells such as human, monkey, mouse, hamster, and frog cells, for example THP-1 cells, MC3T3-E1 cells, XTC cells, Mv1Lu cells, CHO cells, and COS cells; cultured cells of lower eukaryotic cells including, for example, fungi such as the fungi of

genus *Aspergillus* such as *Aspergillus niger*; or yeasts including, for example, the yeasts of genus *Saccharomyces* such as *Saccharomyces cereviceae*, and the like. As the host cell, furthermore, prokaryotic cells including, for example, bacteria such as *Escherichia coli* may be used.

[0035] When the desired DNA is to be expressed in these hosts, an expression-regulating sequence such as a suitable promoter is used depending on the host. In the expression in animal cells, for example, a plasmid containing each of promoters such as pCDM8, pSV, and pEP is used, and in yeast hosts, a plasmid such as pNV11 is used, and in *Escherichia coli*, a plasmid such as pGEMEX and pUEX is used.

[0036] Transformed hosts may be cultured in a conventional method. The polypeptides or proteins of the present invention can be produced using a transgenic animal (Glaser, V., SPECTRUM Biotechnology Applications, 1993) and an insect such as silkworm (Maeda, S. et al., Nature (1985) 315, 592-594) as a host. Recovery and/or purification of polypeptides and proteins thus produced may be accomplished by a commonly used method for enzyme purification such as centrifugation, filtration, gel filtration chromatography, and affinity chromatography.

[0037] Kinases activated by TGF- $\beta$  that carries the signal transduction system of the TGF- $\beta$  family of the present invention are useful for use in the search of drugs that inhibit or promote signaling of TGF- $\beta$  and its superfamily known to be involved in various diseases.

#### Examples

[0038] The present invention will now be explained in further details with reference to the following examples.

#### Example 1. Construction of cDNA library

[0039] cDNA was synthesized from poly(A)-RNA from a mouse IL-3-dependent cell line BAF-BO3 according to a conventional method and was then inserted into a yeast expression vector pNV11 (Ninomiya-Tsuji, J. et al., Proc. Natl. Acad. Sci. U.S.A. 88, 9006-9010 (1991)) shown in Fig. 1 under the control of the TDH3 promoter to construct a cDNA library.

#### Example 2. Screening of cDNA library

[0040] A cDNA library prepared in Example 1 was screened using *Saccharomyces cereviceae* SY1984-P (his3 $\Delta$ , ste11 $\Delta$ , FUS1p::HIS3, STE7P368). In this yeast, Ste11 has been mutated and the activity is deficient in the signal transduction system of mating pheromone, and the FUS1 upstream activation sequence has been ligated to the HIS3 open reading frame to form a reporter gene. The yeast strain is deficient in the original his3 and thus it can grow only when exogenous histidine is present in the culture medium or when the mutation-derived deficiency in the Ste11 activity has been complemented.

[0041] *S. cerevisiae* SY1984-P was transformed with various plasmids. The plasmids used were YCplac22 (vector), pRS314PGKMEKKCT (expresses MEKK $\Delta$ N (K.J. Blumer et al., Proc. Natl. Acad. Sci. U.S.A. Vol. 91, 4925 (1994) that lacks the N-terminal domain downstream of the PGK1 promoter), and pADU-Raf $\Delta$ N (expresses Raf $\Delta$ N (K.Irie et al., Science Vol. 265 1716 (1994) that lacks the N-terminal domain downstream of the ADH1 promoter). These transformants were plated onto a SC-His plate that lacks histidine and were incubated at 30°C. As a result, the yeast that was transformed with the YCplac22 vector did not grow but the yeast transformed with pRS314PGKMEKKCT or pADU-Raf $\Delta$ N did. This confirmed that the screening system is effective.

[0042] Then the above screening system yeast strain YS1984-P was transformed with the cDNA library constructed in Example 1 and then was screened on an SC-His plate to obtain one positive clone pNV11-HU11. The cDNA of this clone was designated as TAK1 $\Delta$ N cDNA. The nucleotide sequence of this cDNA was determined by the dideoxy nucleotide chain termination method. The nucleotide sequence corresponds to the sequence of nucleotides 223 to 1893 set forth in SEQ ID NO: 1 and the amino acid sequence encoded by it corresponds to Ser at position 23 to Ser at position 579 of the amino acid sequence set forth in SEQ ID NO: 1.

[0043] Then, in order to clone the full-length cDNA, the above TAK1 $\Delta$ N cDNA was radiolabeled and used as a probe to further screen the cDNA library obtained in Example 1. Thus, multiple positive clones were obtained. The cDNA of this clone was subcloned into the EcoRI site of pBS vector (manufactured by Stratagene) to obtain pGS-TAK1-5'. This clone was a full-length clone containing the initiation codon ATG. The cDNA was designated as TAK1 cDNA. The nucleotide sequence thereof is shown set forth in SEQ ID NO: 1. The full-length amino acid sequence of Met at position 1 to Ser at position 579 has been encoded in nucleotides 1 to 2443 in the above sequence.

#### Example 3. Tissue distribution of TAK1 gene

[0044] Total RNA was extracted from various tissues of mice and was subjected to Northern blotting using the above

radiolabeled TAK1 cDNA as a probe to find that RNA that hybridizes with TAK1 cDNA was expressed in all the tissues or organs tested (spleen, thymus, lung, heart, liver and brain). It was present at high levels in the spleen, thymus, and brain, and at low levels in the lung, heart, and the liver.

#### Example 4. Properties of TAK1 kinase

[0045] In order to study the functions of the kinase activated by TGF- $\beta$  in mammalian cells, TAK1 cDNA and TAK1 $\Delta$ N cDNA were inserted into a mammalian expression vector pEF (H. Shibuya et al., Nature Vol. 357, 700 (1992)) under the control of the human elongation factor (EF) promoter to obtain expression plasmids pEF-TAK1 and pEF-TAK1 $\Delta$ N. The expression plasmids pEF-TAK1 and pEF-TAK1 $\Delta$ N contain a full-length TAK1 coding sequence and TAK1 $\Delta$ N coding sequence, respectively, under the control of the EF promoter.

[0046] Thus, 2.3 kb of XhoI fragment of pNV11-HU11 was inserted into a XhoI gap of pBS to obtain pBS-TAK1 $\Delta$ N. pEF-MSS1 (H. Shibuya et al., Nature Vol. 357, 700 (1992)) was cleaved with EcoRI and XbaI, into which were introduced a synthetic EcoRI-XhoI linker (sense strand: 5'-AATTCGCCACCATGGC-3') (SEQ ID NO: 2); antisense strand: 5'-TCGAGCCATGGTGGCG-3') (SEQ ID NO: 3) (containing the initiation codon ATG), and an XhoI-HindIII fragment and a HindIII-XbaI fragment from pBS-TAK1 $\Delta$ N to construct pEF-TAK1 $\Delta$ N. pBS was cleaved with EcoRI and XhoI, into which were inserted an EcoRI-SacI fragment from pBS-TAK1 $\Delta$ -5' and a SacI-XhoI fragment from pBS-TAK1 $\Delta$ N to obtain pBS-TAK1 containing the full-length cDNA of TAK1 (TAK1 cDNA). pEF-MSS1 was cleaved with EcoRI and SalI, into which was inserted an EcoRI-SacI fragment from pBS-TAK1 to construct pEF-TAK1.

[0047] *E. coli* having the plasmid pEF-TAK1 has been internationally deposited under the provisions of the Budapest Treaty as *Escherichia coli* MC1061/P3 (pEF-TAK1) and *E. coli* having the plasmid pEF-TAK1 $\Delta$ N as *Escherichia coli* MC1061/P3 (pEF-TAK1 $\Delta$ N) on September 29, 1995 with the National Institute of Bioscience and Human Technology, the Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibaraki pref., Japan, as FERM BP-5246 and FERM BP-5245, respectively.

[0048] The TAK1 gene contained in the plasmid pEF-TAK1 can be excised using an appropriate restriction enzyme such as EcoRI and BamHI.

[0049] A study of the effects of TAK1 on the induction of gene expression by various ligands has revealed that TAK1 has an effect on gene induction by TGF- $\beta$ . An initial cellular response to TGF- $\beta$  induces an elevation in the mRNA level of plasminogen activator inhibitor 1 (PAI-1) (M.R. Keeton et al., J. Biol. Chem. Vol. 266, 23048 (1991)).

[0050] In order to study the effects of TAK1 on TGF- $\beta$  response, TGF- $\beta$  reporter plasmid p800neoLUC containing a luciferase gene regulated by the PAI-1 promoter induced by TGF- $\beta$  (M. Abe et al., Analyt. Biochem., Vol. 216, 276 (1994)) was transiently transfected to MvLu lung epithelial cells by the calcium phosphate method (H. Shibuya et al., Nature Vol. 357, 700 (1992)). In this method of measurement, the luciferase activity induced by TGF- $\beta$  can be measured by the transfection of p800neoLUC onto the MvLu lung epithelial cells. The MvLu cells transiently transfected by p800neoLUC responded to TGF- $\beta$  with a 4- to 5-fold enhanced reporter gene activity. This result is shown in the vector section of Fig. 2.

[0051] The previously constructed TAK1 or TAK1 $\Delta$ N expression plasmid was transiently transfected into MvLu cells. Expression of TAK1 slightly enhanced the expression of TGF- $\beta$ -derived genes and TAK1 $\Delta$ N constitutively activated the expression of the PAI-1 gene (the section of TAK1 $\Delta$ N of Fig. 2). The level of constitutive expression of a reporter gene by TAK1 $\Delta$ N is equal to that in a transfectant treated with TGF- $\beta$ . Thus, the activated TAK1 (i.e. TAK1 $\Delta$ N) can transfer signals in the absence of TGF- $\beta$ . Furthermore, when TGF- $\beta$  was added to a TAK1 $\Delta$ N transfectant, the expression of the PAI-1 gene was further enhanced.

[0052] In Fig. 2, the open bars represent a case in which no induction of TGF- $\beta$  was conducted, and the shaded bars represent a case in which the induction of TGF- $\beta$  was conducted. In the above experiment, cells after transfection were cultured for 20 hours in the presence or absence of human TGF- $\beta$ 1 (30 ng/ml) to prepare an extract from the cells, and luciferase was measured as described in H. Shibuya et al., Mol. Cell. Biol. Vol. 14, 5812 (1994). In the graph of Fig. 2, relative luciferase activities of cells transformed by a vector (containing no TAK1 gene) are shown with the luciferase activity in the absence of TGF- $\beta$ 1 induction being set as 1. The results of bar graphs represent the mean of results of triplicate runs per experiment.

[0053] In order to confirm that the above results are mediated by the kinase activity of TAK1, a catalytically inactive TAK1 $\Delta$ N-K63W was constructed. This was carried out by site-directed mutagenesis using PCR. In this vector, lysine at position 63 in the ATP binding site has been replaced with tryptophan. The mutation is expected to inactivate the kinase activity and signaling activity of TAK1 $\Delta$ N. When TAK1 $\Delta$ N-K63W is co-transfected with p800neoLUC, the ability of constitutively stimulating the expression of the PAI-1 gene was lost (Fig. 2). These results suggest that the kinase activity of TAK1 $\Delta$ N is required for the TGF- $\beta$ -independent expression of PAI-1 gene. Furthermore, a kinase-negative TAK1 $\Delta$ N caused the partial reduction of TGF- $\beta$ -induced expression. These results suggest that TAK1 may act as a mediator of a TGF- $\beta$ -mediated route of signal transduction.

[0054] In order to obtain direct evidence that TAK1 functions in the TGF- $\beta$ -mediated route of signal transduction, it

was determined whether the treatment of cells with TGF- $\beta$  could activate the kinase activity of TAK1. For the identification of an appropriate foreign substrate, an *in vitro* kinase reaction was conducted for TAK1 that was immunoprecipitated from yeast cells expressing TAK1 labeled with a hemagglutinin (HA) epitope (TAK1-HA) (a DNA sequence encoding an epitope recognized by anti-HA monoclonal antibody 12CA5 was ligated by PCR reaction to the 3'-terminal frame of DNA encoding TAK1).

[0055] The results of the immune complex kinase determination indicate that the activated form of TAK1 can phosphorylate and activate the XMEK2/SEK1 subfamily of MAPKK (B.M. Yashar et al., *Nature* Vol. 372, 794 (1994)). On the other hand, the phosphorylation of the original MAPKK-MEK1 (E. Nishida et al., *Trends Biochem. Sci.*, 128 (1993); K.J. Blumer et al., *ibid* Vol. 19, 286 (1994); R.J. Davis, *ibid* Vol. 19, 470 (1990); C.L. Marchall, *Cell*, Vol. 80, 179 (1995)), histone and myelin basic protein was not detected. Thus, TAK1 kinase activity can be measured for its ability of activating XMEK2 *in vitro*.

[0056] Constructs for the expression of HA epitope-labeled TAK1 (HA-TAK1) were made in the following manner. A synthetic oligonucleotide encoding an HA epitope Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala (SEQ ID NO: 4) that is recognized by a monoclonal antibody 12CA5 was cloned into a Sall site (+3 position from the ATG codon) and an EcoRI site of pBS-TAK1 to construct pBS-HA-TAK1. pEF-MSS1 was cleaved with EcoRI and Sall, to which was inserted an EcoRI-XhoI fragment from pBS-HA-TAK1 to construct pEF-HA-TAK1.

[0057] In order to construct pBS-HA-TAK1 $\Delta$ N, pNV11-HU11 was digested with XhoI and HindIII. The fragment obtained was isolated and inserted into a HincII-HindIII site of pBS-HA-TAK1. pEF-MSS1 was cleaved with EcoRI and Sall, into which was inserted a PstI-XhoI fragment from pBS-HA-TAK1 $\Delta$ H to construct pBS-HA-TAK1 $\Delta$ N. Both of these constructs have two copies of the N-terminal HA epitope expressed from the EF promoter.

[0058] These constructs pEF-HA-TAK1 or pEF-HA-TAK1 $\Delta$ H were transiently transfected to the MC3T3-E1 mouse osteoblast (S. Ohta et al., *FEBS Lett.* Vol. 314, 356 (1992)). After stimulation by TGF- $\beta$ 1, the expressed HA-TAK1 was isolated by immunoprecipitation, and its activity was measured by the coupled kinase assay (S. Matsuda et al., *J. Biol. Chem.* Vol. 270, 12969 (1995)).

[0059] Thus, the transfected cells were treated with TGF- $\beta$ 1 (20 ng/ml) or BMP-4 (100 ng/ml) for 0 minute (untreated) to 30 minutes. The cells were scraped into a buffer solution (S. Matsuda et al., *J. Biol. Chem.* Vol. 270, 12781 (1995); T. Moriguchi et al., *J. Biol. Chem.* Vol. 270, 12969 (1995)), and the cellular extract was centrifuged at 15,000  $\times$  g for 10 minutes. The supernatant thus obtained was subjected to immunoprecipitation by anti-HA antibody. Thus, 300  $\mu$ l aliquots of the above supernatant were mixed with 20  $\mu$ l of antibody or 20  $\mu$ l of protein A Sepharose, and the immune complex was washed twice with PBS, which was then used for kinase measurement (S. Matsuda et al., *J. Biol. Chem.* Vol. 270, 12781 (1995); T. Moriguchi et al., *J. Biol. Chem.* Vol. 270, 12969 (1995)).

[0060] Activity was expressed as an incremental multiple relative to the HA-TAK1 activity of non-stimulated cells. The activity of immunoprecipitated TAK1 was measured by its ability of activating recombinant XMEK2/SEK1 (S. Matsuda et al., *J. Biol. Chem.* Vol. 270, 12781 (1995); T. Moriguchi et al., *J. Biol. Chem.* Vol. 270, 12781 (1995)).

[0061] It has already been confirmed that HA-TAK1 does not directly phosphorylate KN-p38/MPK2. In accordance with the immunoblotting of each immunoprecipitate by anti-HA antibody, almost identical amounts of HA-TAK1 were recovered at each point of immunoprecipitation.

[0062] The result of the above experiment indicated that TAK1 kinase activity started to rise within five minutes after stimulation by TGF- $\beta$ , reached a peak at 10 minutes, and returned to an almost baseline level within 30 minutes (Fig. 3). Moreover, TGF- $\beta$ 1 stimulated TAK1 kinase activity in a dose-dependent manner (Fig. 4). Then, it was determined whether TAK1 could be activated by BMP, a member of the TGF- $\beta$  superfamily (A.H. Reddi et al., *Curr. Opin. Genet. Dev.* Vol. 4, 737 (1994)), or epithelial growth factor (EGF). Interestingly, BMP-4 also activated TAK1 kinase in a time- and dose-dependent manner (Fig. 4).

[0063] On the other hand, the activation of TAK1 was not observed in the cells treated with EGF. It is believed that the lack of TAK1 induction by EGF is not because MC3T3-E1 cells do not respond to EGF but because EGF signals are not mediated by TAK1. This is also apparent from the fact that EGF induces the expression of *fos* in MC3T3-E1 cells. Taken together, these data indicate that TAK1 is activated by the TGF- $\beta$  superfamily.

[0064] TAK1 $\Delta$ N can activate the expression of PAI-1 gene independently of TGF- $\beta$  (Fig. 2), which suggests that TAK1 $\Delta$ N protein has an enhanced kinase activity even in the absence of TGF- $\beta$  treatment in the cell. In order to study this possibility, TAK1 $\Delta$ N labeled with the HA epitope (HA-TAK1 $\Delta$ N) (see above) was transiently transfected to MC3T3-E1 cells, and the activity of TAK1 $\Delta$ N was determined by the immunocomplex kinase measurement. Thus, MC3T3-E1 cells were transfected by pEF-HA-TAK1 $\Delta$ N, and from the transfected cells HA-TAK1 $\Delta$ N was immunoprecipitated as described above and its activity was measured.

[0065] All the data are expressed as an incremental multiple from the HA-TAK1 activity of non-stimulated cells.

[0066] As shown in Fig. 4, TAK1 $\Delta$ N protein has a considerably higher inherent kinase activity supporting the hypothesis that the TAK1 $\Delta$ N lacking the 22 amino acid residues at the N-terminal are constitutively active.

Example 5. Construction of cDNA library

[0067] From human T-cell cell line Jurkat cells, poly(A)RNA was prepared and cDNA was synthesized in a conventional method. This was inserted into a yeast expression vector pNV7 (Ninomiya-Tsuji, J. et al., Proc. Natl. Acad. Sci. U.S.A. 88, 9006-9010 (1991)) downstream of TDH3 promoter to construct a cDNA library.

Example 6. Screening of cDNA library

[0068] A mutant *Saccharomyces cereviceae* lacking the activity of Ssk2/Ssk22 and Sho1 that act in the signal transduction system of high osmotic pressure stress can grow in the YEPD medium (Yeast extract 10 g/l, tryptone 20 g/l, glucose 20 g/l), but not in a medium with 1M sorbitol added thereto (T. Maeda et al., Science, 269, 554 (1995)). Therefore, by introducing cDNA into this mutant followed by screening, a cDNA that can complement the deficient Ssk2/Ssk22 activity can be isolated.

[0069] In fact, a *Saccharomyces cereviceae* strain deficient in the Ssk2/Ssk22 and Sho1 activity described in the above reference (ssk2Δ, ssk22Δ, sho1Δ) was transformed with pNV11-HU11 (mouse TAK1ΔN) obtained in Example 2. The transformant was plated to the YEPD plate containing 1M sorbitol and was incubated at 30°C for 30 minutes. As a result, the yeast transformed with pNV11-HU11 grew even under a high osmotic pressure stress. This confirmed that the screening system is effective.

[0070] Then, this *Saccharomyces cereviceae* strain (ssk2Δ, ssk22Δ, sho1Δ) was transformed with the cDNA library constructed in Example 5, and was screened under a high osmotic pressure stress (incubated at 30°C in a YEPD medium containing 1M sorbitol). As a result, one positive clone pNV7-hTAK1 was obtained. cDNA contained in this clone was amplified using the PRISM Dye Terminator Cycle Sequencing kit (manufactured by Perkin Elmer) and the base sequence thereof was determined. The base sequence and the corresponding amino acid sequence were as set forth in SEQ ID NO: 5. The base sequence of this cDNA had a 92% homology with that of mouse TAK1, and the amino acid sequence encoded by the cDNA had a 99% homology with that of mouse TAK1. Comparisons of the base sequence of mouse TAK1 and human TAK1 are shown in Fig. 5 through Fig. 9, and those of the amino acid sequence are shown in Fig. 10 and Fig. 11.

[0071] Human TAK1 cDNA was subcloned into pUC19 that had been digested with Sall to obtain a plasmid pHAK1 containing the full-length cDNA of human TAK1. *E. coli* having the plasmid pHAK1 was internationally designated as *Escherichia coli* JM109 (pHAK1) under the provisions of the Budapest Treaty on July 19, 1996 with the National Institute of Bioscience and Human Technology, the Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibalaki pref., Japan, as FERM BP-5598.

Deposit of microorganisms

[0072] The following microorganisms were deposited with the Patent Microorganism Depository in the National Institute of Bioscience and Human Technology, the Agency of Industrial Science and Technology, of 1-3, Higashi 1-chome, Tsukuba city, Ibalaki pref., Japan, and were assigned the following accession numbers:

Organism: *Escherichia coli* MC1061/P3 (pEF-TAK1)  
 Date deposited: September 28, 1995  
 Accession number: FERM BP-5246  
 Organism: *Escherichia coli* MC1061/P3 (pEF-TAK1ΔN)  
 Date deposited: September 28, 1995  
 Accession number: FERM BP-5245  
 Organism: *Escherichia coli* JM109 (pHAK1)  
 Date deposited: July 19, 1996  
 Accession number: FERM BP-5598



## SEQUENCE LISTINGS

5 SEQ ID NO: 1

Sequence Length: 2443

10 Sequence Type: Nucleic acid

Strandedness: Single

Topology: Linear

15 Molecular Type: cDNA

Sequence

20 GAATTCGGCA CGAGGAGGAG CCGAAGCCGG GACTCGGCGG TGGCCCGGGT CGGTCCCGCG 60

CCACGGAGCG CCGGGCGGCG GGCTGCGGGG CTCGGGGCTG AAGGGCGCTG CGCGAGCCGG 120

AGGGCGGGCG CGGCCCCCGG GCGCCGCGG GGGATC ATG TCG ACA GCC TCC GCC 174

25 Met Ser Thr Ala Ser Ala

1 5

30 GCC TCG TCC TCC TCC TCG TCT TCT GCC AGT GAG ATG ATC GAA GCG CCG 222

Ala Ser Ser Ser Ser Ser Ser Ser Ala Ser Glu Met Ile Glu Ala Pro

10 15 20

35 TCG CAG GTC CTG AAC TTC GAA GAG ATC GAC TAC AAG GAG ATC GAG GTG 270

Ser Gln Val Leu Asn Phe Glu Glu Ile Asp Tyr Lys Glu Ile Glu Val

25 30 35

40 GAA GAG GTT GTC GGA AGA GGA GCT TTT GGA GTA GTT TGC AAA GCT AAG 318

Glu Glu Val Val Gly Arg Gly Ala Phe Gly Val Val Cys Lys Ala Lys

45 40 45 50

50 TGG AGA GCA AAA GAT GTC GCT ATT AAA CAG ATA GAA AGT GAG TCT GAG 366

Trp Arg Ala Lys Asp Val Ala Ile Lys Gln Ile Glu Ser Glu Ser Glu

55 60 65 70

55

EP 0 919 621 A1

	AGG AAG GCT TTC ATT GTG GAG CTC CGG CAG TTG TCG CGT GTG AAC CAT	414
5	Arg Lys Ala Phe Ile Val Glu Leu Arg Gln Leu Ser Arg Val Asn His	
	75 80 85	
	CCT AAC ATT GTC AAG TTG TAC GGA GCC TGC CTG AAT CCA GTA TGT CTT	462
10	Pro Asn Ile Val Lys Leu Tyr Gly Ala Cys Leu Asn Pro Val Cys Leu	
	90 95 100	
	GTG ATG GAA TAT GCA GAG GGG GGC TCA TTG TAT AAT GTG CTG CAT GGT	510
15	Val Met Glu Tyr Ala Glu Gly Gly Ser Leu Tyr Asn Val Leu His Gly	
	105 110 115	
	GCT GAA CCA TTG CCT TAC TAC ACT GCT GCT CAT GCC ATG AGC TGG TGT	558
20	Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala His Ala Met Ser Trp Cys	
	120 125 130	
	TTA CAG TGT TCC CAA GGA GTG GCT TAC CTG CAC AGC ATG CAG CCC AAA	606
25	Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu His Ser Met Gln Pro Lys	
	135 140 145 150	
30	GCG CTG ATT CAC AGG GAC CTC AAG CCT CCA AAC TTG CTG CTG GTT GCA	654
	Ala Leu Ile His Arg Asp Leu Lys Pro Pro Asn Leu Leu Leu Val Ala	
35	155 160 165	
	GGA GGG ACA GTT CTA AAA ATC TGC GAT TTT GGT ACA GCT TGT GAC ATC	702
40	Gly Gly Thr Val Leu Lys Ile Cys Asp Phe Gly Thr Ala Cys Asp Ile	
	170 175 180	
	CAA ACA CAC ATG ACC AAT AAT AAA GGG AGT GCT GCT TGG ATG GCG CCT	750
45	Gln Thr His Met Thr Asn Asn Lys Gly Ser Ala Ala Trp Met Ala Pro	
	185 190 195	
	GAA GTG TTT GAA GGT AGC AAT TAC AGT GAA AAG TGT GAT GTC TTC AGC	798
50	Glu Val Phe Glu Gly Ser Asn Tyr Ser Glu Lys Cys Asp Val Phe Ser	
	200 205 210	
55		

EP 0 919 621 A1

	TGG GGT ATT ATC CTC TGG GAA GTG ATA ACA CGC CGG AAA CCC TTC GAT	846
5	Trp Gly Ile Ile Leu Trp Glu Val Ile Thr Arg Arg Lys Pro Phe Asp	
	215                      220                      225                      230	
	GAG ATC GGT GGC CCA GCT TTC AGA ATC ATG TGG GCT GTT CAT AAT GGC	894
10	Glu Ile Gly Gly Pro Ala Phe Arg Ile Met Trp Ala Val His Asn Gly	
	235                      240                      245	
15	ACT CGA CCA CCA CTG ATC AAA AAT TTA CCT AAG CCC ATT GAG AGC TTG	942
	Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro Lys Pro Ile Glu Ser Leu	
	250                      255                      260	
20	ATG ACA CGC TGT TGG TCT AAG GAC CCA TCT CAG CGC CCT TCA ATG GAG	990
	Met Thr Arg Cys Trp Ser Lys Asp Pro Ser Gln Arg Pro Ser Met Glu	
	265                      270                      275	
25	GAA ATT GTG AAA ATA ATG ACT CAC TTG ATG CGG TAC TTC CCA GGA GCG	1038
	Glu Ile Val Lys Ile Met Thr His Leu Met Arg Tyr Phe Pro Gly Ala	
30	280                      285                      290	
	GAT GAG CCA TTA CAG TAT CCT TGT CAG TAC TCT GAT GAA GGG CAG AGC	1086
	Asp Glu Pro Leu Gln Tyr Pro Cys Gln Tyr Ser Asp Glu Gly Gln Ser	
35	295                      300                      305                      310	
	AAC TCA GCC ACC AGC ACA GGC TCG TTC ATG GAC ATT GCT TCT ACA AAT	1134
40	Asn Ser Ala Thr Ser Thr Gly Ser Phe Met Asp Ile Ala Ser Thr Asn	
	315                      320                      325	
45	ACC AGT AAT AAA AGT GAC ACA AAT ATG GAA CAG GTT CCT GCC ACA AAC	1182
	Thr Ser Asn Lys Ser Asp Thr Asn Met Glu Gln Val Pro Ala Thr Asn	
	330                      335                      340	
50	GAC ACT ATT AAA CGC TTG GAG TCA AAA CTG TTG AAA AAC CAG GCA AAG	1230
	Asp Thr Ile Lys Arg Leu Glu Ser Lys Leu Leu Lys Asn Gln Ala Lys	
	345                      350                      355	

55

EP 0 919 621 A1

	CAA CAG AGT GAA TCT GGA CGC CTG AGC TTG GGA GCC TCT CGT GGG AGC	1278
5	Gln Gln Ser Glu Ser Gly Arg Leu Ser Leu Gly Ala Ser Arg Gly Ser	
	360 365 370	
	AGT GTG GAG AGC TTG CCC CCC ACT TCC CAG GGC AAG AGG ATG AGT GCT	1326
10	Ser Val Glu Ser Leu Pro Pro Thr Ser Glu Gly Lys Arg Met Ser Ala	
	375 380 385 390	
	GAC ATG TCT GAA ATA GAA GCC AGG ATC GTG GCG ACT GCA GGT AAC GGG	1374
15	Asp Met Ser Glu Ile Glu Ala Arg Ile Val Ala Thr Ala Gly Asn Gly	
	395 400 405	
20	CAA CCA AGG CGT AGA TCC ATC CAA GAC TTG ACT GTT ACT GGG ACA GAA	1422
	Gln Pro Arg Arg Arg Ser Ile Gln Asp Leu Thr Val Thr Gly Thr Glu	
	410 415 420	
25	CCT GGT CAG GTG AGC AGC CGG TCA TCC AGC CCT AGT GTC AGA ATG ATC	1470
	Pro Gly Gln Val Ser Ser Arg Ser Ser Ser Pro Ser Val Arg Met Ile	
	425 430 435	
30	ACT ACC TCA GGA CCA ACC TCA GAG AAG CCA GCT CGC AGT CAC CCA TGG	1518
	Thr Thr Ser Gly Pro Thr Ser Glu Lys Pro Ala Arg Ser His Pro Trp	
35	440 445 450	
	ACC CCT GAT GAT TCC ACA GAC ACC AAT GGC TCA GAT AAC TCC ATC CCA	1566
	Thr Pro Asp Asp Ser Thr Asp Thr Asn Gly Ser Asp Asn Ser Ile Pro	
40	455 460 465 470	
	ATG GCG TAT CTT ACA CTG GAT CAC CAG CTA CAG CCT CTA GCG CCG TGC	1614
	Met Ala Tyr Leu Thr Leu Asp His Gln Leu Gln Pro Leu Ala Pro Cys	
45	475 480 485	
	CCA AAC TCC AAA GAA TCC ATG GCA GTG TTC GAA CAG CAC TGT AAA ATG	1662
50	Pro Asn Ser Lys Glu Ser Met Ala Val Phe Glu Gln His Cys Lys Met	
	490 495 500	
55		

EP 0 919 621 A1

5 GCA CAG GAG TAT ATG AAA GTT CAA ACC GAA ATC GCA TTG TTA CTA CAG 1710  
 Ala Gln Glu Tyr Met Lys Val Gln Thr Glu Ile Ala Leu Leu Leu Gln  
 505 510 515

10 AGA AAG CAA GAA CTA GTT GCA GAA TTG GAC CAG GAT GAA AAG GAC CAG 1758  
 Arg Lys Gln Glu Leu Val Ala Glu Leu Asp Gln Asp Glu Lys Asp Gln  
 520 525 530

15 CAA AAT ACA TCT CGT CTG GTA CAG CAA CAT AAA AAG CTT TTA GAT GAA 1806  
 Gln Asn Thr Ser Arg Leu Val Gln Glu His Lys Lys Leu Leu Asp Glu  
 535 540 545 550

20 AAC AAA AGC CTT TCT ACT TAT TAC CAG CAA TGC AAA AAA CAA CTA GAG 1854  
 Asn Lys Ser Leu Ser Thr Tyr Tyr Gln Gln Cys Lys Lys Gln Leu Glu  
 555 560 565

25 GTC ATC AGA AGC CAA CAG CAG AAA CGA CAA GGC ACT TCA TGATTCTCTG 1903  
 Val Ile Arg Ser Gln Gln Gln Lys Arg Gln Gly Thr Ser  
 570 575

30 GGACCGTTAC GTTTTAAAAT ATGCAAAGAC CTTTTTTTAA GAGAAGACAA ACCATTATAA 1963  
 CAGTTCATGA GTGTTAGCTT TTTGGCGTGT TCTGAATGCC AAATGCCTCT CTTTGCTGCA 2023

35 TTTGTTATGT CAGTTACCTT TCTTCTTATG GTGGATATAA AATCCACTGT CGTGTTGCAG 2083  
 CAGATGATGG CACCTGTGGC TTGGCAAGGC GAGSGTGCTC AGCTTCAGGG GCACATGAAG 2143  
 TGAACCTGGC TGTATGTGCA TGCTCCTGGA GTGAGCTACC TAACAGGAGG GGGTAGCACA 2203

40 CTGGCTACTG TGTGCAGGCA TCATCCTTTC TCTGTAGTAA AAGGTGGGAC CTCAAGAATT 2263  
 TTCTTCAAAG TGCTCATCTC AAAAACTGA TTTTTTCCC AGTAGATGGT ATGCTCCAAT 2323

45 GTAAAGACAG AGTATTAAAA TAACCTGTGG TACATTACAG AGGGACAGAA TGTGAGGCT 2384  
 GAGTTCAAAG ACAGGGTTTG TGCCAACACA TCCTGGCTTT AGAGCACAAT GGATCTCGAG 2443

SEQ ID NO: 2

Sequence Length: 16

Sequence Type: Nucleic acid

Strandedness: Single

Topology: Linear

Molecular Type: Synthetic DNA

Sequence

AATTCGCCAC CATGGC

16

SEQ ID NO: 3

Sequence Length: 16

Sequence Type: Nucleic acid

Strandedness: Single

Topology: Linear

Molecular Type: Synthetic DNA

Sequence

TCGAGCCATG GTGGCG

16

SEQ ID NO: 4

Sequence Length: 27

Sequence Type: Amino acid

Topology: Linear

Molecular Type: Peptide

Sequence

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala

1

5

SEQ ID NO: 5

Sequence Length: 2656

Sequence Type: Nucleic acid

Strandedness: Single

Topology: Linear

Molecular Type: cDNA

EP 0 919 621 A1

Sequence

5 GTCGAGATCC ATTGTGCTCT AAAGACGGCT GTGGCCGCTG CCTCTACCCC CGCCACGGAT 60  
 CGCCGGGTAG TAGGACTGCG CGGCTCCAGG CTGAGGGTCG GTCCGGAGGC GGGTGGGCGC 120  
 GGGTCTCACC CGGATTGTCC GGGTGGCACC GTTCCCGGCC CCACCGGGCG CCGCGAGGGA 180  
 10 TC ATG TCT ACA GCC TCT GCC GCC TCC TCC TCC TCC TCG TCT TCG GCC 227  
 Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ser Ala  
 1 5 10 15  
 15 GGT GAG ATG ATC GAA GCC CCT TCC CAG GTC CTC AAC TTT GAA GAG ATC 275  
 Gly Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu Ile  
 20 20 25 30  
 GAC TAC AAG GAG ATC GAG GTG GAA GAG GTT GTT GGA AGA GGA GCC TTT 323  
 Asp Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly Ala Phe  
 25 35 40 45  
 GGA GTT GTT TGC AAA GCT AAG TGG AGA GCA AAA GAT GTT GCT ATT AAA 371  
 30 Gly Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val Ala Ile Lys  
 50 55 60  
 CAA ATA GAA AGT GAA TCT GAG AGG AAA GCG TTT ATT GTA GAG CTT CGG 419  
 35 Gln Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile Val Glu Leu Arg  
 65 70 75  
 40 CAG TTA TCC CGT GTG AAC CAT CCT AAT ATT GTA AAG CTT TAT GGA GCC 467  
 Gln Leu Ser Arg Val Asn His Pro Asn Ile Val Lys Leu Tyr Gly Ala  
 80 85 90 95  
 45 TGC TTG AAT CCA GTG TGT CTT GTG ATG GAA TAT GCT GAA GGG GGC TCT 515  
 Cys Leu Asn Pro Val Cys Leu Val Met Glu Tyr Ala Glu Gly Gly Ser  
 50 100 105 110  
 55

EP 0 919 621 A1

	TTA TAT AAT GTG CTG CAT GGT GCT GAA CCA TTG CCA TAT TAT ACT GCT	563
	Leu Tyr Asn Val Leu His Gly Ala Glu Pro Leu Pro Tyr Tyr Thr Ala	
5	115 120 125	
	GCC CAC GCA ATG AGT TGG TGT TTA CAG TGT TCC CAA GGA GTG GCT TAT	611
10	Ala His Ala Met Ser Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr	
	130 135 140	
	CTT CAC AGC ATG CAA CCC AAA GCG CTA ATT CAC AGG GAC CTG AAA CCA	659
15	Leu His Ser Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro	
	145 150 155	
	CCA AAC TTA CTG CTG GTT GCA GGG GGG ACA GTT CTA AAA ATT TGT GAT	707
20	Pro Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp	
	160 165 170 175	
	TTT GGT ACA GCC TGT GAC ATT CAG ACA CAC ATG ACC AAT AAC AAG GGG	755
25	Phe Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys Gly	
	180 185 190	
	AGT GCT GCT TGG ATG GCA CCT GAA GTT TTT GAA GGT AGT AAT TAC AGT	803
30	Ser Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser Asn Tyr Ser	
	195 200 205	
	GAA AAA TGT GAC GTC TTC AGC TGG GGT ATT ATT CTT TGG GAA GTG ATA	851
	Glu Lys Cys Asp Val Phe Ser Trp Gly Ile Ile Leu Trp Glu Val Ile	
40	210 215 220	
	ACG CGT CGG AAA CCC TTT GAT GAG ATT GGT GGC CCA GCT TTC CGA ATC	899
	Thr Arg Arg Lys Pro Phe Asp Glu Ile Gly Gly Pro Ala Phe Arg Ile	
45	225 230 235	
	ATG TGG GCT GTT CAT AAT GGT ACT CGA CCA CCA CTG ATA AAA AAT TTA	947
50	Met Trp Ala Val His Asn Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu	
	240 245 250 255	

55



EP 0 919 621 A1

	CCT AAG CCC ATT GAG AGC CTG ATG ACT CGT TGT TGG TCT AAA GAT CCT	995
5	Pro Lys Pro Ile Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro	
	260 265 270	
	TCC CAG CGC CCT TCA ATG GAG GAA ATT GTG AAA ATA ATG ACT CAC TTG	1043
10	Ser Gln Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu	
	275 280 285	
	ATG CGG TAC TTT CCA GGA GCA GAT GAG CCA TTA CAG TAT CCT TGT CAG	1091
15	Met Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln	
	290 295 300	
	TAT TCA GAT GAA GGA CAG AGC AAC TCT GCC ACC AGT ACA GGC TCA TTC	1139
20	Tyr Ser Asp Glu Gly Gln Ser Asn Ser Ala Thr Ser Thr Gly Ser Phe	
	305 310 315	
	ATG GAC ATT GCT TCT ACA AAT ACG AGT AAC AAA AGT GAC ACT AAT ATG	1187
25	Met Asp Ile Ala Ser Thr Asn Thr Ser Asn Lys Ser Asp Thr Asn Met	
	320 325 330 335	
30	GAG CAA GTT CCT GCC ACA AAT GAT ACT ATT AAG CGC TTA GAA TCA AAA	1235
	Glu Gln Val Pro Ala Thr Asn Asp Thr Ile Lys Arg Leu Glu Ser Lys	
	340 345 350	
35	TTG TTG AAA AAT CAG GCA AAG CAA CAG AGT GAA TCT GGA CGT TTA AGC	1283
	Leu Leu Lys Asn Gln Ala Lys Gln Gln Ser Glu Ser Gly Arg Leu Ser	
40	355 360 365	
	TTG GGA GCC TCC CAT GGG AGC AGT GTG GAG AGC TTG CCC CCA ACC TCT	1331
45	Leu Gly Ala Ser His Gly Ser Ser Val Glu Ser Leu Pro Pro Thr Ser	
	370 375 380	
	GAG GGC AAG AGG ATG AGT GCT GAC ATG TCT GAA ATA GAA GCT AGG ATC	1379
50	Glu Gly Lys Arg Met Ser Ala Asp Met Ser Glu Ile Glu Ala Arg Ile	
	385 390 395	

55

EP 0 919 621 A1

GCC GCA ACC ACA GGC AAC GGA CAG CCA AGA CGT AGA TCC ATC CAA GAC 1427  
 Ala Ala Thr Thr Gly Asn Gly Gln Pro Arg Arg Arg Ser Ile Gln Asp  
 5 400 405 410 415  
 TTG ACT GTA ACT GGA ACA GAA CCT GGT CAG GTG AGC AGT AGG TCA TCC 1475  
 10 Leu Thr Val Thr Gly Thr Glu Pro Gly Gln Val Ser Ser Arg Ser Ser  
 420 425 430  
 AGT CCC AGT GTC AGA ATG ATT ACT ACC TCA GGA CCA ACC TCA GAA AAG 1523  
 15 Ser Pro Ser Val Arg Met Ile Thr Thr Ser Gly Pro Thr Ser Glu Lys  
 435 440 445  
 CCA ACT CGA AGT CAT CCA TGG ACC CCT GAT GAT TCC ACA GAT ACC AAT 1571  
 20 Pro Thr Arg Ser His Pro Trp Thr Pro Asp Asp Ser Thr Asp Thr Asn  
 450 455 460  
 GGA TCA GAT AAC TCC ATC CCA ATG GCT TAT CTT ACA CTG GAT CAC CAA 1619  
 25 Gly Ser Asp Asn Ser Ile Pro Met Ala Tyr Leu Thr Leu Asp His Gln  
 465 470 475  
 CTA CAG CCT CTA GCA CCG TGC CCA AAC TCC AAA GAA TCT ATG GCA GTG 1667  
 30 Leu Gln Pro Leu Ala Pro Cys Pro Asn Ser Lys Glu Ser Met Ala Val  
 480 485 490 495  
 TTT GAA CAG CAT TGT AAA ATG GCA CAA GAA TAT ATG AAA GTT CAA ACA 1715  
 35 Phe Glu Gln His Cys Lys Met Ala Gln Glu Tyr Met Lys Val Gln Thr  
 40 500 505 510  
 GAA ATT GCA TTG TTA TTA CAG AGA AAG CAA GAA CTA GTT GCA GAA CTG 1763  
 45 Glu Ile Ala Leu Leu Leu Gln Arg Lys Gln Glu Leu Val Ala Glu Leu  
 515 520 525  
 GAC CAG GAT GAA AAG GAC CAG CAA AAT ACA TCT CGC CTG GTA CAG GAA 1811  
 50 Asp Gln Asp Glu Lys Asp Gln Gln Asn Thr Ser Arg Leu Val Gln Glu  
 530 535 540

55

EP 0 919 621 A1

CAT AAA AAG CTT TTA GAT GAA AAC AAA AGC CTT TCT ACT TAC TAC CAG 1859  
 5 His Lys Lys Leu Leu Asp Glu Asn Lys Ser Leu Ser Thr Tyr Tyr Gln  
 545 550 555  
 CAA TGC AAA AAA CAA CTA GAG GTC ATC ACA AGT CAG CAG CAG AAA CGA 1907  
 10 Gln Cys Lys Lys Gln Leu Glu Val Ile Arg Ser Gln Gln Gln Lys Arg  
 560 565 570 575  
 15 CAA GGC ACT TCA TGATTCTCTG GGACCGTTAC ATTTTGAAAT ATGCAAAGAA 1959  
 Gln Gly Thr Ser  
 AGACTTTTTT TTTAAGGAAA GGAAACCTT ATAATGACGA TTCATGAGTG TTAGCTTTTT 2019  
 20 GGCGTGTCT GAATGCCAAC TGCCTATATT TGCTGCATTT TTTTCATTGT TTATTTTCCT 2079  
 TTTCTCATGG TGGACATACA ATTTTACTGT TTCATTGCAT AACATGGTAG CATCTGTGAC 2139  
 25 TTGAATGAGC AGCACTTTGC AACTTCAAAA CAGATGCAGT GAACTGTGGC TGTATATGCA 2199  
 TGCTCATTGT GTGAAGGCTA GCCTAACAGA ACAGGAGGTA TCAAACCTAGC TGCTATGTGC 2259  
 AAACAGCGTC CATTTTTTCA TATTAGAGGT GGAACCTCAA GAATGACTTT ATTCTTGTAT 2319  
 30 CTCATCTCAA AATATTAATA ATTTTTTTCC CAAAAGATGG TATATACCAA GTTAAAGACA 2379  
 GGGTATTATA AATTTAGAGT GATTGGTGGT ATATTACGGA AATACGGAAC CTTTAGGGAT 2439  
 35 AGTTCCGTGT AAGGGCTTTG ATGCCAGCAT CCTTGGATCA GACTGAACT CAGTTCCATC 2499  
 CGTAAATAT GTAAAGGTAA GTGGCAGCTG CTCTATTTAA TGAAAGCAGT TTTACCGGAT 2559  
 40 TTTGTTAGAC TAAAATTGA TTGTGATACA TTGAACAAAA TGGAATCAT TTTTTTAAAG 2619  
 GAGTAAAGAT TTTCTTTAGA GCACAATGGA TCTCGAC 2656

45

50

55

## SEQUENCE LISTING

5 <110> Chugai Seiyaku Kabushiki Kaisha  
 <120> Human TAKI and DNA encoding the same  
 10 <130> D901/PCT  
 <140> PCT/JP97/01050  
 <141> 1997-03-27  
 15 <150> US 08/685,625  
 JP 8-256747  
 20 <151> 1996-07-24  
 1996-09-27  
 <160> 7  
 25 <210> 1  
 <211> 2443  
 30 <212> DNA  
 <213> Human  
 35 <223> Nucleotide Sequence of TAKI cDNA  
 <400> 1  
 gaattcggca cgaggaggag ccgaagccgg gactcggcgg tggcccgggt cggccccgcg 60  
 40 ccacggagcg ccgggcggcg ggctgcgggg ctccgggctg aagggcgctg cgcgagccgg 120  
 agggcgggcg cggccccccg ggccgcgcgg gggatc atg tcg aca gcc tcc gcc 174  
 Met Ser Thr Ala Ser Ala  
 45 1 5  
 gcc tcg tcc tcc tcc tcg tct tct gcc agt gag atg atc gaa gcg ccg 222  
 50 Ala Ser Ser Ser Ser Ser Ser Ser Ala Ser Glu Met Ile Glu Ala Pro  
 10 15 20

55

EP 0 919 621 A1

	tcg cag gtc ctg aac ttc gaa gag atc gac tac aag gag atc gag ggc	270
5	Ser Gln Val Leu Asn Phe Glu Glu Ile Asp Tyr Lys Glu Ile Glu Val	
	25 30 35	
	gaa gag gtt gtc gga aga gga gct ttt gga gta gtt tgc aaa gct aag	318
10	Glu Glu Val Val Gly Arg Gly Ala Phe Gly Val Val Cys Lys Ala Lys	
	40 45 50	
	tgg aga gca aaa gat gtc gct att aaa cag ata gaa agt gag tct gag	366
15	Trp Arg Ala Lys Asp Val Ala Ile Lys Gln Ile Glu Ser Glu Ser Glu	
	55 60 65 70	
20	agg aag gct ttc att gtg gag ctc cgg cag ttg tcg cgt gtg aac cat	414
	Arg Lys Ala Phe Ile Val Glu Leu Arg Gln Leu Ser Arg Val Asn His	
	75 80 85	
25	cct aac att gtc aag ttg tac gga gcc tgc ctg aat cca gta tgt ctt	462
	Pro Asn Ile Val Lys Leu Tyr Gly Ala Cys Leu Asn Pro Val Cys Leu	
	90 95 100	
30	gtg atg gaa tat gca gag ggg ggc tca ttg tat aat gtg ctg cat ggt	510
	Val Met Glu Tyr Ala Glu Gly Gly Ser Leu Tyr Asn Val Leu His Gly	
35	105 110 115	
	gct gaa cca ttg cct tac tac act gct gct cat gcc atg agc tgg tgt	558
	Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala His Ala Met Ser Trp Cys	
40	120 125 130	
	tta cag tgt tcc caa gga gtg gct tac ctg cac agc atg cag ccc aaa	606
45	Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu His Ser Met Gln Pro Lys	
	135 140 145 150	
	gcg ctg att cac agg gac ctc aag cct cca aac ttg ctg ctg gtt gca	654
50	Ala Leu Ile His Arg Asp Leu Lys Pro Pro Asn Leu Leu Leu Val Ala	
	155 160 165	
55		

EP 0 919 621 A1

5 gga ggg aca gtt cta aaa atc tgc gat ttt ggt aca gct tgt gac atc 702  
 Gly Gly Thr Val Leu Lys Ile Cys Asp Phe Gly Thr Ala Cys Asp Ile  
 170 175 180  
 10 caa aca cac atg acc aat aat aaa ggg agt gct gct tgg atg gcg cct 750  
 Gln Thr His Met Thr Asn Asn Lys Gly Ser Ala Ala Trp Met Ala Pro  
 185 190 195  
 15 gaa gtg ttt gaa ggt agc aat tac agt gaa aag tgt gat gtc ttc agc 798  
 Glu Val Phe Glu Gly Ser Asn Tyr Ser Glu Lys Cys Asp Val Phe Ser  
 200 205 210  
 20 tgg ggt att atc ctc tgg gaa gtg ata aca cgc cgg aaa ccc ttc gat 846  
 Trp Gly Ile Ile Leu Trp Glu Val Ile Thr Arg Arg Lys Pro Phe Asp  
 215 220 225 230  
 25 gag atc ggt ggc cca gct ttc aga atc atg tgg gct gtt cat aat ggc 894  
 Glu Ile Gly Gly Pro Ala Phe Arg Ile Met Trp Ala Val His Asn Gly  
 235 240 245  
 30 act cga cca cca ctg atc aaa aat tta cct aag ccc att gag agc ttg 942  
 Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro Lys Pro Ile Glu Ser Leu  
 250 255 260  
 35 atg aca cgc tgt tgg tct aag gac cca tct cag cgc cct tca atg gag 990  
 Met Thr Arg Cys Trp Ser Lys Asp Pro Ser Gln Arg Pro Ser Met Glu  
 265 270 275  
 40 gaa att gtg aaa ata atg act cac ttg atg cgg tac ttc cca gga gcg 1038  
 Glu Ile Val Lys Ile Met Thr His Leu Met Arg Tyr Phe Pro Gly Ala  
 280 285 290  
 45 gat gag cca tta cag tat cct tgt cag tac tct gat gaa ggg cag agc 1086  
 Asp Glu Pro Leu Gln Tyr Pro Cys Gln Tyr Ser Asp Glu Gly Gln Ser  
 295 300 305 310  
 55

EP 0 919 621 A1

aac tca gcc acc agc aca ggc tgc ttc atg gac att gct tct aca aat 1134  
 Asn Ser Ala Thr Ser Thr Gly Ser Phe Met Asp Ile Ala Ser Thr Asn  
 5 315 320 325  
 acc agt aat aaa agt gac aca aat atg gaa cag gtt cct gcc aca aac 1182  
 10 Thr Ser Asn Lys Ser Asp Thr Asn Met Glu Gln Val Pro Ala Thr Asn  
 330 335 340  
 gac act att aaa cgc ttg gag tca aaa ctg ttg aaa aac cag gca aag 1230  
 15 Asp Thr Ile Lys Arg Leu Glu Ser Lys Leu Leu Lys Asn Gln Ala Lys  
 345 350 355  
 caa cag agt gaa tct gga cgc ctg agc ttg gga gcc tct cgt ggg agc 1278  
 20 Gln Gln Ser Glu Ser Gly Arg Leu Ser Leu Gly Ala Ser Arg Gly Ser  
 360 365 370  
 agt gtg gag agc ttg ccc ccc act tcc gag ggc aag agg atg agt gct 1326  
 25 Ser Val Glu Ser Leu Pro Pro Thr Ser Glu Gly Lys Arg Met Ser Ala  
 375 380 385 390  
 gac atg tct gaa ata gaa gcc agg atc gtg gcg act gca ggt aac ggg 1374  
 30 Asp Met Ser Glu Ile Glu Ala Arg Ile Val Ala Thr Ala Gly Asn Gly  
 395 400 405  
 caa cca agg cgt aga tcc atc caa gac ttg act gtt act ggg aca gaa 1422  
 40 Gln Pro Arg Arg Arg Ser Ile Gln Asp Leu Thr Val Thr Gly Thr Glu  
 410 415 420  
 cct ggt cag gtg agc agc cgg tca tcc agc cct agt gtc aga atg atc 1470  
 45 Pro Gly Gln Val Ser Ser Arg Ser Ser Ser Pro Ser Val Arg Met Ile  
 425 430 435  
 act acc tca gga cca acc tca gag aag cca gct cgc agt cac cca tgg 1518  
 50 Thr Thr Ser Gly Pro Thr Ser Glu Lys Pro Ala Arg Ser His Pro Trp  
 440 445 450  
 55

EP 0 919 621 A1

acc cct gat gat tcc aca gac acc aat ggc tca gat aac tcc atc cca 1566  
 Thr Pro Asp Asp Ser Thr Asp Thr Asn Gly Ser Asp Asn Ser Ile Pro  
 5 455 460 465 470  
 atg gcg tat ctt aca ctg gat cac cag cta cag cct cta gcg ccg tgc 1614  
 10 Met Ala Tyr Leu Thr Leu Asp His Gln Leu Gln Pro Leu Ala Pro Cys  
 475 480 485  
 cca aac tcc aaa gaa tcc atg gca gtg ttc gaa cag cac tgt aaa atg 1662  
 15 Pro Asn Ser Lys Glu Ser Met Ala Val Phe Glu Gln His Cys Lys Met  
 490 495 500  
 gca cag gag tat atg aaa gtt caa acc gaa atc gca ttg tta cta cag 1710  
 20 Ala Gln Glu Tyr Met Lys Val Gln Thr Glu Ile Ala Leu Leu Leu Gln  
 505 510 515  
 aga aag caa gaa cta gtt gca gaa ttg gac cag gat gaa aag gac cag 1758  
 25 Arg Lys Gln Glu Leu Val Ala Glu Leu Asp Gln Asp Glu Lys Asp Gln  
 520 525 530  
 caa aat aca tct cgt ctg gta cag gaa cat aaa aag ctt tta gat gaa 1806  
 30 Gln Asn Thr Ser Arg Leu Val Gln Glu His Lys Lys Leu Leu Asp Glu  
 535 540 545 550  
 aac aaa agc ctt tct act tat tac cag caa tgc aaa aaa caa cta gag 1854  
 35 Asn Lys Ser Leu Ser Thr Tyr Tyr Gln Gln Cys Lys Lys Gln Leu Glu  
 40 555 560 565  
 gtc atc aga agc caa cag cag aaa cga caa ggc act tca tgattctctg 1903  
 45 Val Ile Arg Ser Gln Gln Gln Lys Arg Gln Gly Thr Ser  
 570 575  
 ggaccgttac gttttaaaat atgcaaagac ctttttttaa gagaagacaa accattataa 1963  
 50 cagttcatga gtgtagctt tttggcgtgt tctgaatgcc aaatgcctct ctttgctgca 2023  
 tttgttatgt cagttacctt tcttcttatg gtggatataa aatccactgt cgtgttgacg 2083  
 55



# EP 0 919 621 A1

5 cagatgatgg cacctgtggc ttgggaaggc gagsgtgtrc agcttcaggc gcccatgag 2143  
 tgaacctggc tgtatgtgca tgctcctgga gtgagctacc taacaggagg gggtagcaca 2203  
 ctggctactg tgtgcaggca tcatccttc tctgtagtaa aagggtgggac ctcaagaatt 2263  
 ttcttcaaag tgctcatctc aaaaatctga ttttttccc agtagatggg atgctccaat 2323  
 10 gtaaagacag agtattaataa taacttgtgg tacattacag agggacagaa tggtgaggct 2384  
 gagttcaaag acagggtttg tgccaacaca tcctggcttt agagcacaat ggatctcgag 2443

<210> 2  
 15 <211> 16  
 <212> DNA  
 <213> Artificial Sequence  
 20 <220>  
 <221>  
 25 <222>  
 <223> Linker  
 <400> 2

30 aattcgccac catggc 16

<210> 3  
 35 <211> 16  
 <212> DNA  
 <213> Artificial Sequence  
 40 <220>  
 <221>  
 <222>  
 45 <223> Linker  
 <400> 3

50 tcgagccatg gtggcg 16

<210> 4

55

EP 0 919 621 A1

<211> 9  
 <212> PRT  
 5 <213> Artificial  
 <220>  
 10 <221>  
 <223> Epitope Sequence  
 <400> 4  
 15 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala  
 1 5  
 20 <210> 5  
 <211> 2656  
 <212> DNA  
 25 <213> Human  
 <220>  
 30 <221>  
 <223> Nucleotide Sequence of TAKI cDNA  
 <400> 5  
 35 gtcgagatcc attgtgctct aaagacggct gtggccgctg cctctacccc cgccacggat 60  
 cgccgggtag taggactgcg cggctccagg ctgagggctg gtccggaggc ggggtgggcgc 120  
 40 ggggtctcacc cggattgtcc ggggtggcacc gttcccgccc ccaccgggcg ccgcgaggga 180  
 tc atg tct aca gcc tct gcc gcc tcc tcc tcc tcc tcc tcc tcc tcc tcc 227  
 Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ser Ala  
 45 1 5 10 15  
 ggt gag atg atc gaa gcc cct tcc cag gtc ctc aac ttt gaa gag atc 275  
 50 Gly Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu Ile  
 20 25 30

EP 0 919 621 A1

gac tac aag gag atc gag gtg gaa gag gtt gtt gga aga gga gcc ttt 323  
 Asp Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly Ala Phe  
 5 35 40 45  
 gga gtt gtt tgc aaa gct aag tgg aga gca aaa gat gtt gct att aaa 371  
 Gly Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val Ala Ile Lys  
 10 50 55 60  
 caa ata gaa agt gaa tct gag agg aaa gcg ttt att gta gag ctt cgg 419  
 Gln Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile Val Glu Leu Arg  
 15 65 70 75  
 cag tta tcc cgt gtg aac cat cct aat att gta aag ctt tat gga gcc 467  
 Gln Leu Ser Arg Val Asn His Pro Asn Ile Val Lys Leu Tyr Gly Ala  
 20 80 85 90 95  
 tgc ttg aat cca gtg tgt ctt gtg atg gaa tat gct gaa ggg ggc tct 515  
 Cys Leu Asn Pro Val Cys Leu Val Met Glu Tyr Ala Glu Gly Gly Ser  
 25 100 105 110  
 tta tat aat gtg ctg cat ggt gct gaa cca ttg cca tat tat act gct 563  
 Leu Tyr Asn Val Leu His Gly Ala Glu Pro Leu Pro Tyr Tyr Thr Ala  
 30 115 120 125  
 gcc cac gca atg agt tgg tgt tta cag tgt tcc caa gga gtg gct tat 611  
 Ala His Ala Met Ser Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr  
 35 130 135 140  
 ctt cac agc atg caa ccc aaa gcg cta att cac agg gac ctg aaa cca 659  
 Leu His Ser Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro  
 40 145 150 155  
 cca aac tta ctg ctg gtt gca ggg ggg aca gtt cta aaa att tgt gat 707  
 Pro Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp  
 45 160 165 170 175  
 50  
 55

EP 0 919 621 A1

	ttt ggt aca gcc tgt gac att cag aca cac atg acc aat aac aag ggg	755
	Phe Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys Gly	
5	180 185 190	
	agt gct gct tgg atg gca cct gaa gtt ttt gaa ggt agt aat tac agt	803
10	Ser Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser Asn Tyr Ser	
	195 200 205	
	gaa aaa tgt gac gtc ttc agc tgg ggt att att ctt tgg gaa gtg ata	851
15	Glu Lys Cys Asp Val Phe Ser Trp Gly Ile Ile Leu Trp Glu Val Ile	
	210 215 220	
	acg cgt cgg aaa ccc ttt gat gag att ggt ggc cca gct ttc cga atc	899
20	Thr Arg Arg Lys Pro Phe Asp Glu Ile Gly Gly Pro Ala Phe Arg Ile	
	225 230 235	
	atg tgg gct gtt cat aat ggt act cga cca cca ctg ata aaa aat tta	947
25	Met Trp Ala Val His Asn Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu	
	240 245 250 255	
30	cct aag ccc att gag agc ctg atg act cgt tgt tgg tct aaa gat cct	995
	Pro Lys Pro Ile Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro	
	260 265 270	
35	tcc cag cgc cct tca atg gag gaa att gtg aaa ata atg act cac ttg	1043
	Ser Gln Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu	
40	275 280 285	
	atg cgg tac ttt cca gga gca gat gag cca tta cag tat cct tgt cag	1091
45	Met Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln	
	290 295 300	
	tat tca gat gaa gga cag agc aac tct gcc acc agt aca ggc tca ttc	1139
50	Tyr Ser Asp Glu Gly Gln Ser Asn Ser Ala Thr Ser Thr Gly Ser Phe	
	305 310 315	
55		

EP 0 919 621 A1

atg gac att gct tct aca aat acg agt aac aaa agt gac act aat atg 1187  
 5 Met Asp Ile Ala Ser Thr Asn Thr Ser Asn Lys Ser Asp Thr Asn Met  
 320 325 330 335  
 gag caa gtt cct gcc aca aat gat act att aag cgc tta gaa tca aaa 1235  
 10 Glu Gln Val Pro Ala Thr Asn Asp Thr Ile Lys Arg Leu Glu Ser Lys  
 340 345 350  
 ttg ttg aaa aat cag gca aag caa cag agt gaa tct gga cgt tta agc 1283  
 15 Leu Leu Lys Asn Gln Ala Lys Gln Gln Ser Glu Ser Gly Arg Leu Ser  
 355 360 365  
 ttg gga gcc tcc cat ggg agc agt gtg gag agc ttg ccc cca acc tct 1331  
 20 Leu Gly Ala Ser His Gly Ser Ser Val Glu Ser Leu Pro Pro Thr Ser  
 370 375 380  
 gag ggc aag agg atg agt gct gac atg tct gaa ata gaa gct agg atc 1379  
 25 Glu Gly Lys Arg Met Ser Ala Asp Met Ser Glu Ile Glu Ala Arg Ile  
 385 390 395  
 gcc gca acc aca ggc aac gga cag cca aga cgt aga tcc atc caa gac 1427  
 30 Ala Ala Thr Thr Gly Asn Gly Gln Pro Arg Arg Arg Ser Ile Gln Asp  
 400 405 410 415  
 ttg act gta act gga aca gaa cct ggt cag gtg agc agt agg tca tcc 1475  
 35 Leu Thr Val Thr Gly Thr Glu Pro Gly Gln Val Ser Ser Arg Ser Ser  
 40 420 425 430  
 agt ccc agt gtc aga atg att act acc tca gga cca acc tca gaa aag 1523  
 45 Ser Pro Ser Val Arg Met Ile Thr Thr Ser Gly Pro Thr Ser Glu Lys  
 435 440 445  
 cca act cga agt cat cca tgg acc cct gat gat tcc aca gat acc aat 1571  
 50 Pro Thr Arg Ser His Pro Trp Thr Pro Asp Asp Ser Thr Asp Thr Asn  
 450 455 460  
 55

EP 0 919 621 A1

gga tca gat aac tcc atc cca atg gct tat ctt aca ctg gat cac caa 1619  
 Gly Ser Asp Asn Ser Ile Pro Met Ala Tyr Leu Thr Leu Asp His Gln  
 5 465 470 475  
 cta cag cct cta gca ccg tgc cca aac tcc aaa gaa tct atg gca gtg 1667  
 10 Leu Gln Pro Leu Ala Pro Cys Pro Asn Ser Lys Glu Ser Met Ala Val  
 480 485 490 495  
 ttt gaa cag cat tgt aaa atg gca caa gaa tat atg aaa gtt caa aca 1715  
 15 Phe Glu Gln His Cys Lys Met Ala Gln Glu Tyr Met Lys Val Gln Thr  
 500 505 510  
 gaa att gca ttg tta tta cag aga aag caa gaa cta gtt gca gaa ctg 1763  
 20 Glu Ile Ala Leu Leu Leu Gln Arg Lys Gln Glu Leu Val Ala Glu Leu  
 515 520 525  
 gac cag gat gaa aag gac cag caa aat aca tct cgc ctg gta cag gaa 1811  
 25 Asp Gln Asp Glu Lys Asp Gln Gln Asn Thr Ser Arg Leu Val Gln Glu  
 530 535 540  
 cat aaa aag ctt tta gat gaa aac aaa agc ctt tct act tac tac cag 1859  
 30 His Lys Lys Leu Leu Asp Glu Asn Lys Ser Leu Ser Thr Tyr Tyr Gln  
 545 550 555  
 caa tgc aaa aaa caa cta gag gtc atc aga agt cag cag cag aaa cga 1907  
 Gln Cys Lys Lys Gln Leu Glu Val Ile Arg Ser Gln Gln Gln Lys Arg  
 40 560 565 570 575  
 caa ggc act tca tgattctctg ggaccgttac attttgaaat atgcaaagaa 1959  
 Gln Gly Thr Ser  
 45 agactttttt tttaaggaaa ggaaaacctt ataatgacga ttcattgagtg ttagcttttt 2019  
 ggctgtgttct gaatgccaac tgcctatatt tgctgcattt ttttcattgt ttatttttct 2079  
 50 tttctcatgg tggacataca attttactgt ttcattgcat aacatggtag catctgtgac 2139  
 ttgaatgagc agcactttgc aacttcaaaa cagatgcagt gaactgtggc tgtatatgca 2199  
 55

EP 0 919 621 A1

tgctcattgt gtgaaggcta gcctaacaga acaggaggta tcaaactagc tgctatgtgc 2259  
 5 aaacagcgtc ctttttttca tattagaggt ggaacctcaa gaatgacttt attcttgtat 2319  
 ctcatctcaa aatattaata atttttttcc caaaagatgg tatataccaa gttaaagaca 2379  
 gggattata aatttagagt gattgggtgt atattacgga aatacggaa ctttagggat 2439  
 10 agttccgtgt aagggtttg atgccagcat ccttgatca gtactgaact cagttccatc 2499  
 cgtaaaatat gtaaaggtaa gtggcagctg ctctatttaa tgaaagcagt ttaccggat 2559  
 tttgttagac taaaatttga ttgtgataca ttgaacaaaa tggaactcat tttttttaag 2619  
 15 gagtaaagat tttctttaga gcacaatgga tctcgac 2656

<210> 6

20 <211> 579

<212> PRT

25 <213> Human

<223> Amino acid Sequence of TAKI

<400> 6

30 Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ser Ala Ser  
 1 5 10 15  
 35 Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu Ile Asp  
 20 25 30  
 Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly Ala Phe Gly  
 40 35 40 45  
 Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val Ala Ile Lys Gln  
 45 50 55 60  
 Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile Val Glu Leu Arg Gln  
 65 70 75 80  
 50 Leu Ser Arg Val Asn His Pro Asn Ile Val Lys Leu Tyr Gly Ala Cys  
 85 90 95

55

EP 0 919 621 A1

5                   Leu Asn Pro Val Cys Leu Val Met Glu Tyr Ala Glu Gly Gly Ser Leu  
                   100                   105                   110  
 Tyr Asn Val Leu His Gly Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala  
                   115                   120                   125  
 10               His Ala Met Ser Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu  
                   130                   135                   140  
 His Ser Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro Pro  
 15               145                   150                   155                   160  
 Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp Phe  
 20                   165                   170                   175  
 Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys Gly Ser  
                   180                   185                   190  
 25               Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser Asn Tyr Ser Glu  
                   195                   200                   205  
 30               Lys Cys Asp Val Phe Ser Trp Gly Ile Ile Leu Trp Glu Val Ile Thr  
                   210                   215                   220  
 Arg Arg Lys Pro Phe Asp Glu Ile Gly Gly Pro Ala Phe Arg Ile Met  
 35               225                   230                   235                   240  
 Trp Ala Val His Asn Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro  
 40                   245                   250                   255  
 Lys Pro Ile Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro Ser  
                   260                   265                   270  
 45               Gln Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu Met  
                   275                   280                   285  
 50               Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln Tyr  
                   290                   295                   300  
 55



EP 0 919 621 A1

Ser Asp Glu Gly Gln Ser Asn Ser Ala Thr Ser Thr Gly Ser Phe Met  
 305 310 315 320  
 5 Asp Ile Ala Ser Thr Asn Thr Ser Asn Lys Ser Asp Thr Asn Met Glu  
 325 330 335  
 10 Gln Val Pro Ala Thr Asn Asp Thr Ile Lys Arg Leu Glu Ser Lys Leu  
 340 345 350  
 15 Leu Lys Asn Gln Ala Lys Gln Gln Ser Glu Ser Gly Arg Leu Ser Leu  
 355 360 365  
 Gly Ala Ser Arg Gly Ser Ser Val Glu Ser Leu Pro Pro Thr Ser Glu  
 20 370 375 380  
 Gly Lys Arg Met Ser Ala Asp Met Ser Glu Ile Glu Ala Arg Ile Val  
 25 385 390 395 400  
 Ala Thr Ala Gly Asn Gly Gln Pro Arg Arg Arg Ser Ile Gln Asp Leu  
 405 410 415  
 30 Thr Val Thr Gly Thr Glu Pro Gly Gln Val Ser Ser Arg Ser Ser Ser  
 420 425 430  
 35 Pro Ser Val Arg Met Ile Thr Thr Ser Gly Pro Thr Ser Glu Lys Pro  
 435 440 445  
 Ala Arg Ser His Pro Trp Thr Pro Asp Asp Ser Thr Asp Thr Asn Gly  
 40 450 455 460  
 Ser Asp Asn Ser Ile Pro Met Ala Tyr Leu Thr Leu Asp His Gln Leu  
 45 465 470 475 480  
 Gln Pro Leu Ala Pro Cys Pro Asn Ser Lys Glu Ser Met Ala Val Phe  
 485 490 495  
 50 Glu Gln His Cys Lys Met Ala Gln Glu Tyr Met Lys Val Gln Thr Glu  
 500 505 510  
 55

EP 0 919 621 A1

Ile Ala Leu Leu Leu Gln Arg Lys Gln Glu Leu Val Ala Glu Leu Asp  
5 515 520 525  
Gln Asp Glu Lys Asp Gln Gln Asn Thr Ser Arg Leu Val Gln Glu His  
530 535 540  
10 Lys Lys Leu Leu Asp Glu Asn Lys Ser Leu Ser Thr Tyr Tyr Gln Gln  
545 550 555 560  
15 Cys Lys Lys Gln Leu Glu Val Ile Arg Ser Gln Gln Gln Lys Arg Gln  
565 570 575  
Gly Thr Ser  
20 <210> 7  
<211> 579  
<212> PRT  
25 <213> Human  
<223> Amino acid Sequence of TAKI  
30 <400> 7  
Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ala Gly  
1 5 10 15  
35 Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu Ile Asp  
20 25 30  
40 Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly Ala Phe Gly  
35 40 45  
Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val Ala Ile Lys Gln  
45 50 55 60  
Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile Val Glu Leu Arg Gln  
65 70 75 80  
50 Leu Ser Arg Val Asn His Pro Asn Ile Val Lys Leu Tyr Gly Ala Cys  
85 90 95  
55

EP 0 919 621 A1

Leu Asn Pro Val Cys Leu Val Met Glu Tyr Ala Glu Gly Gly Ser Leu  
 100 105 110  
 Tyr Asn Val Leu His Gly Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala  
 115 120 125  
 His Ala Met Ser Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu  
 130 135 140  
 His Ser Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro Pro  
 145 150 155 160  
 Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp Phe  
 165 170 175  
 Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys Gly Ser  
 180 185 190  
 Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser Asn Tyr Ser Glu  
 195 200 205  
 Lys Cys Asp Val Phe Ser Trp Gly Ile Ile Leu Trp Glu Val Ile Thr  
 210 215 220  
 Arg Arg Lys Pro Phe Asp Glu Ile Gly Gly Pro Ala Phe Arg Ile Met  
 225 230 235 240  
 Trp Ala Val His Asn Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro  
 245 250 255  
 Lys Pro Ile Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro Ser  
 260 265 270  
 Gln Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu Met  
 275 280 285  
 Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln Tyr  
 290 295 300

EP 0 919 621 A1

Ser Asp Glu Gly Gln Ser Asn Ser Ala Thr Ser Thr Gly Ser Phe Met  
 305 310 315 320  
 5 Asp Ile Ala Ser Thr Asn Thr Ser Asn Lys Ser Asp Thr Asn Met Glu  
 325 330 335  
 10 Gln Val Pro Ala Thr Asn Asp Thr Ile Lys Arg Leu Glu Ser Lys Leu  
 340 345 350  
 15 Leu Lys Asn Gln Ala Lys Gln Gln Ser Glu Ser Gly Arg Leu Ser Leu  
 355 360 365  
 Gly Ala Ser His Gly Ser Ser Val Glu Ser Leu Pro Pro Thr Ser Glu  
 370 375 380  
 20 Gly Lys Arg Met Ser Ala Asp Met Ser Glu Ile Glu Ala Arg Ile Ala  
 385 390 395 400  
 25 Ala Thr Thr Gly Asn Gly Gln Pro Arg Arg Arg Ser Ile Gln Asp Leu  
 405 410 415  
 30 Thr Val Thr Gly Thr Glu Pro Gly Gln Val Ser Ser Arg Ser Ser Ser  
 420 425 430  
 Pro Ser Val Arg Met Ile Thr Thr Ser Gly Pro Thr Ser Glu Lys Pro  
 435 440 445  
 35 Thr Arg Ser His Pro Trp Thr Pro Asp Asp Ser Thr Asp Thr Asn Gly  
 450 455 460  
 40 Ser Asp Asn Ser Ile Pro Met Ala Tyr Leu Thr Leu Asp His Gln Leu  
 465 470 475 480  
 45 Gln Pro Leu Ala Pro Cys Pro Asn Ser Lys Glu Ser Met Ala Val Phe  
 485 490 495  
 50 Glu Gln His Cys Lys Met Ala Gln Glu Tyr Met Lys Val Gln Thr Glu  
 500 505 510  
 55

# EP 0 919 621 A1

Ile Ala Leu Leu Leu Gln Arg Lys Gln Gln Leu Val Ala Glu Leu Asp  
 515 520 525  
 5 Gln Asp Glu Lys Asp Gln Gln Asn Thr Ser Arg Leu Val Gln Glu His  
 530 535 540  
 10 Lys Lys Leu Leu Asp Glu Asn Lys Ser Leu Ser Thr Tyr Tyr Gln Gln  
 545 550 555 560  
 15 Cys Lys Lys Gln Leu Glu Val Ile Arg Ser Gln Gln Gln Lys Arg Gln  
 565 570 575  
 Gly Thr Ser

## Claims

1. A polypeptide having a kinase activity that is activated by transforming growth factor (TGF)- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.
2. A polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5.
3. DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.
4. DNA according to claim 3 having a nucleotide sequence from T at position 249 to A at position 1919 set forth in SEQ ID NO: 5.
5. DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5.
6. DNA according to claim 5 having a nucleotide sequence from A at position 183 to A at position 1919 set forth in SEQ ID NO: 5.
7. A vector comprising DNA according to any of claims 3 to 6.
8. A host cell transformed with a vector comprising DNA according to any of claims 3 to 6.
9. A method for producing a polypeptide having a kinase activity that is activated by TGF- $\beta$ , which method comprises culturing a host cell transformed with a vector comprising DNA according to any of claims 3 to 6 and then recovering the product from the culture.
10. A polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide being produced by the method according to claim 9.
11. A kinase that is activated by TGF- $\beta$ , said kinase comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5.
12. A fusion protein of a protein according to any of claims 1, 2, 10, and 11, and another protein.

Fig.1




Fig.2




Fig.3






Fig.4




Fig.5

```

1' ATGCTACAGCCTCTGCCGCTCCTCCTCCTCCTCGTCTTCGGCCGGTGAGATGATCGAA
   *****
   *****
1" ATGTCGACAGCCTCCGCCCTCGTCTCCTCCTCGTCTTCTGCCAGTGAGATGATCGAA
   *****
   *****
61' GCCCCTTCCCAGGTCCTCAACTTTGAAGAGATCGACTACAAGGAGATCGAGGTGGAAGAG
   ** **
   *****
61" GCGCCGTCGCAGGTCCTGAACCTTCGAAGAGATCGACTACAAGGAGATCGAGGTGGAAGAG
   *****
   *****
121' GTTGTGGAAGAGGAGCCTTTGGAGTTGTTGCAAGCTAAGTGGAGAGCAAAAGATGTT
   *****
   *****
121" GTTGTGGAAGAGGAGCCTTTGGAGTAGTTTGCAAGCTAAGTGGAGAGCAAAAGATGTC
   *****
   *****
181' GCTATTAAACAATAAGTGAAGTGAAGTGAAGGAAAGCGTTTATTGTAGAGCTTCGGCAG
   *****
   *****
181" GCTATTAAACAGATAGAAAGTGAGTCTGAGAGGAAGGCTTTCATTGTGGAGCTCCGGCAG
   *****
   *****
241' TTATCCCGTGTGAACCATCCTAATATTGTAAAGCTTTATGGAGCCTGCTTGAATCCAGTG
   ** **
   *****
241" TTGTCGGGTGTGAACCATCCTAACATTGTCAAGTTGTACGGAGCCTGCCTGAATCCAGTA
   *****
   *****
301' TGTCTTGTGATGGAATATGCTGAAGGGGGCTCTTTATATAATGTGCTGCATGGTCTGAA
   *****
   *****
301" TGTCTTGTGATGGAATATGCAGAGGGGGCTCATTGTATATATGTGCTGCATGGTCTGAA
   *****
   *****

```

Fig.6

```

361' CCATTGCCATATTATACTGCTGCCCCACGCAATGAGTTGGTGTACAGTGTTCCTCCCAAGGA
***** ** ** ***** ** ** ***** *****
361" CCATTGCCCTTACTACACTGCTGCTCATGCCATGAGCTGGTGTACAGTGTTCCTCCCAAGGA

421' GTGGCTTATCTTCACAGCATGCAACCCAAAGCGCTAATTCACAGGGACCTGAAACCCACCA
***** ** ***** ***** ***** ** **
421" GTGGCTTACCTGCACAGCATGCAGGCCCAAGCCCTGATTCACAGGGACCTCAAGCCTCCA

481' AACTTACTGCTGGTTGCAGGGGGACAGTCTCTAAAAATTGTGATTTTGGTACAGCCTGT
***** ***** ***** ** *****
481" AACTTGCTGCTGGTTGCAGGGGACAGTCTCTAAAAATCTGCGATTTTGGTACAGCTTGT

541' GACATTCAGACACACATGACCAATAACAAGGGGAGTGTGCTTGGATGGCACCTGAAGTT
***** ** ***** ** *****
541" GACATCCAAACACACATGACCAATAATAAAGGGAGTGTGCTTGGATGGCGCCTGAAGTG

601' TTTGAAGGTAGTAATTACAGTGAAAAATGTGACGTCTTCAGCTGGGGTATTATTCTTTGG
***** ***** ***** *****
601" TTTGAAGGTAGCAATTACAGTGAAAAAGTGTGATGCTTTCAGCTGGGGTATTATCCTCTGG

```

Fig. 7

661' GAAGTGATAACGCGTCGGAAACCCCTTTGATGAGATTGGTGGCCAGCTTCCGGAATCATG  
 \*\*\*\*\* \*\* \*\*\*\*\*  
 661" GAAGTGATAACACGCGCGGAAACCCCTTCGATGAGATCGGTGGCCAGCTTTCAGAAATCATG  
 \*\*\*\*\* \*\* \*\*\*\*\*  
 721' TGGGCTGTTTCATAATGGTACTCGACCACTGATAAAAAATTTACCTAAAGCCCATTTGAG  
 \*\*\*\*\*  
 721" TGGGCTGTTTCATAATGGCACTCGACCACTGATCAAAAAATTTACCTAAGCCCATTTGAG  
 \*\*\*\*\*  
 781' AGCCTGATGACTCGTGTGGTCTAAAGATCCTTCCAGCGCCCTTCAATGGAGGAAATT  
 \*\*\* \*\*\*\*\* \*\* \*\*\*\*\*  
 781" AGCTTGATGACACGCTGTGGTCTAAGGACCCATCTCAGCGCCCTTCAATGGAGGAAATT  
 \*\*\*\*\*  
 841' GTGAAATAATGACTCATTGATGCGGTACTTTCCAGGAGCAGATGAGCCATTACAGTAT  
 \*\*\*\*\*  
 841" GTGAAATAATGACTCATTGATGCGGTACTTTCCAGGAGCGGATGAGCCATTACAGTAT  
 \*\*\*\*\*  
 901' CCTTGTCAGTATTCAGATGAAGGACAGAGCAACTCTGCCACCAGTACAGGCTCATTCATG  
 \*\*\*\*\* \*\* \*\*\*\*\*  
 901" CCTTGTCAGTACTCTGTATGAAGGCGCAGAGCAACTCAGCCACCAGCAGGCTCGTTCATG  
 \*\*\*\*\*  
 961' GACATTGCTTCTACAAATACGAGTAACAAAAGTGACACTAATATGGAGCAAGTTCCTGCC  
 \*\*\*\*\*  
 961" GACATTGCTTCTACAAATACGAGTAATAAAAAGTGACACAATAATATGGAACAGGTTCTCTGCC

Fig. 8

```

1021' ACAATGATACATTAAAGCGCTAGAAATCAAAATTTGTTGAAAAATCAGGCAAGCAACAG
      ***** ** ***** ** ***** ** ***** ** ***** ** *****
1021" ACAACGACACTATTAAACGCTTGGAGTCAAAACTGTTGAAAAACCAGGCAAGCAACAG
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

1081' AGTGAATCTGGACGTTTAAGCTTGGAGCCTCCCATGGGAGCAGTGTGGAGAGCTTGCCC
      ***** ** ***** ** ***** ** ***** ** ***** ** *****
1081" AGTGAATCTGGAGCGCTGAGCTTGGAGCCTCTCGTGGAGCAGTGTGGAGAGCTTGCCC
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

1141' CCAACCTCTGAGGGCAAGAGGATGAGTGTGACATGTCTGAAATAGAGCTAGGATCGCC
      ** ** ** ***** ** ***** ** ***** ** ***** ** *****
1141" CCCACTTCGAGGGCAAGAGGATGAGTGTGACATGTCTGAAATAGAGCAGGATCGTG
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

1201' GCAACCAAGGCAACGGACAGCCAGAGCTAGATCCATCCAGACTTGACTGTAACCTGGA
      ** ** ** ***** ** ***** ** ***** ** ***** ** *****
1201" GCGACTGCAGGTACGGGCAACCAAGCGGTAGATCCATCCAGACTTGACTGTTACTGGG
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

1261' ACAGAACCTGGTCAGGTGAGCAGTAGGTCTATCCAGTCCAGTGTCAAGATGATTACTACC
      ***** ** ***** ** ***** ** ***** ** ***** ** *****
1261" ACAGAACCTGGTCAGGTGAGCAGCGGTCATCCAGCCCTAGTGTCAAGATGATCACTACC
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

1321' TCAGGACCAACCTCAGAAAAGCCAACTCGAAGTCATCCATGGACCCCTGATGATTCACACA
      ***** ** ***** ** ***** ** ***** ** ***** ** *****
1321" TCAGGACCAACCTCAGAGAAGCCAGCTCGCAGTCACCCATGGACCCCTGATGATTCACACA
      ***** ** ***** ** ***** ** ***** ** ***** ** *****

```

Fig. 9

```

1381' GATACCAATGGATCAGATAAATCCCAATGGCTTATCTTACACTGGATCACCAACTA
** *****
1381" GACACCAATGGCTCAGATAAATCCCAATGGCTATCTTACACTGGATCACCAAGTA
*****

1441' CAGCCTCTAGCACCGTGCCCAAACTCCAAGAATCTATGGCAGTGTGTTGAACAGCATTGT
*****
1441" CAGCCTCTAGCGCCGTGCCCAAACTCCAAGAATCCATGGCAGTGTTCGAACAGCATTGT
*****

1501' AAAATGGCACAGAATAATATGAAAGTTCAAACAGAAATTCATTGTTATTACAGAGAAAG
*****
1501" AAAATGGCACAGGAGTATATGAAAGTTCAAACCGAAATCGCATTTGTTACTACAGAGAAAG
*****

1561' CAAGAAGTAGTTGCAGAACTGGACCCAGGATGAAAAGGACCAGCAAAATACATCTCGCCTG
*****
1561" CAAGAAGTAGTTGCAGAAATGGACCCAGGATGAAAAGGACCAGCAAAATACATCTCGTCTG
*****

1621' GTACAGGAACATAAAAAGCTTTTAGATGAAAACAAAAGCCTTTCTACTTACTACCAGCAA
*****
1621" GTACAGGAACATAAAAAGCTTTTAGATGAAAACAAAAGCCTTTCTACTTATTACCAGCAA
*****

1681' TGCAAAAACAACTAGAGGTCATCAGAAAGTCAGCAGCAGAGAAACGACAGGCACTTCATGA
*****
1681" TGCAAAAACAACTAGAGGTCATCAGAAAGCCACAGCAGAGAAACGACAGGCACTTCATGA
*****

```

Fig.10

```

1'  MSTASAASSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDV
    *****
1"  MSTASAASSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDV
    *****

61'  AIKQIESESEKAFIVELRQLSRVNHPIVKLYGACLPVCLVMEYAEGGSLYNVLHGAE
    *****
61"  AIKQIESESEKAFIVELRQLSRVNHPIVKLYGACLPVCLVMEYAEGGSLYNVLHGAE
    *****

121'  PLPYYTAAHAMSWCQLQCSQGVAYLHSMQPKALIHRLKPPNLLLVAGGTVLKICDFGTAC
    *****
121"  PLPYYTAAHAMSWCQLQCSQGVAYLHSMQPKALIHRLKPPNLLLVAGGTVLKICDFGTAC
    *****

181'  DIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIIILWEVITRRKPFDEIGGPAFRIM
    *****
181"  DIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIIILWEVITRRKPFDEIGGPAFRIM
    *****

241'  WAVHNGTRPPLIKNLPKPIESLMTRCWSKDP SQRPSMEEIVKIMTHLMRYFPGADEPLQY
    *****
241"  WAVHNGTRPPLIKNLPKPIESLMTRCWSKDP SQRPSMEEIVKIMTHLMRYFPGADEPLQY
    *****

```

Fig.11

301' PCQYDEGQNSATSTGSEMDIASTNTSNKSDTNMEQVPATNDTIKRLESKLLKNQAKQQ  
\*\*\*\*\*  
301" PCQYDEGQNSATSTGSEMDIASTNTSNKSDTNMEQVPATNDTIKRLESKLLKNQAKQQ  
\*\*\*\*\*  
361' SESGRLSLGASHGSSVESLPPTSEGRKMSADMSEIEARIAATTGNGQPRRRSIQDLTVTG  
\*\*\*\*\*.  
361" SESGRLSLGASHGSSVESLPPTSEGRKMSADMSEIEARIVATAGNGQPRRRSIQDLTVTG  
\*\*\*\*\*.  
421' TEPGVSSRRSSPSVRMITTSIPTSEKPTRSHPWTPDDSTDTNGSDNSIPMAYLTLDHQL  
\*\*\*\*\*.  
421" TEPGVSSRRSSPSVRMITTSIPTSEKPARSHPWTPDDSTDTNGSDNSIPMAYLTLDHQL  
\*\*\*\*\*  
481' QPLAPCPNSKESMAVFEQHCKMAQYMKVQTEIALLLQKQELVAELDQDEKQDQNTSRL  
\*\*\*\*\*  
481" QPLAPCPNSKESMAVFEQHCKMAQYMKVQTEIALLLQKQELVAELDQDEKQDQNTSRL  
\*\*\*\*\*  
541' VQEHKKLLDENKSLSTYYQOCKKKQLEVIRSQQKQKGTS  
\*\*\*\*\*  
541" VQEHKKLLDENKSLSTYYQOCKKKQLEVIRSQQKQKGTS  
\*\*\*\*\*



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/01050

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl <sup>6</sup> C12N15/54, C12P21/02, C12N9/12, C12N1/21		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
Int. Cl <sup>6</sup> C12N15/54, C12P21/02, C12N9/12, C12N1/21		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CAS ONLINE, BIOSIS, WPI/WPI,L		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science 270 1995 K. Yamaguchi et al. "Identification of a member of the MAPKKK Family as a potential mediator of TGF- $\beta$ signal transduction" p. 2008-2011	1 - 12
Y	Hyuga Saito and others "New Molecular Genetics for Bio-Science (in Japanese)" (Nankodo) 1987 p. 235-236	12
A	Cell 80 1995 C.J. Marshall "Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation" p. 179-185	1 - 12
A	Science 265 1994 J.F. Smothers et al. "Stimulatory effects of yeast and mammalian 14-3-3 proteins on the raf protein kinase" p. 1716-1719	1 - 12
A	Science 241 1988 Steven K. Hanks et al. "The protein kinase family: conserved features and	1 - 12
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document: member of the same patent family		
Date of the actual completion of the international search June 24, 1997 (24. 06. 97)		Date of mailing of the international search report July 8, 1997 (08. 07. 97)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer  Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/01050

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	deduced phylogeny of the catalytic domains" p. 42-52	
Y	Nature 324 1986 Randall K. Saiki et al. "Analysis of enzymatically amplified $\beta$ -globin and HLA-DQ $\alpha$ DNA with allele-specific oligonucleotide probes" p. 163-166	1 - 12

Form PCT/ISA/210 (continuation of second sheet) (July 1992)



European Patent  
Office

**SUPPLEMENTARY  
EUROPEAN SEARCH REPORT**

0919621

Application Number  
EP 97 90 8525

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
T	SAKURAI, H. ET AL.: "TGF-beta-Activated Kinase 1 Stimulates NF-kappaB Activation by an NF-kappaB-Inducing Kinase-Independent Mechanism" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 243, no. 2, 13 February 1998 (1998-02-13), pages 545-549, XP000867678 * page 545, column 2, line 32 - page 546, column 1, line 14 * * page 546, column 1, line 60 - column 2, line 11 * * page 547; figure 1A * -----	1-12	C12N15/54 C12P21/02 C12N9/12 C12N1/21
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N C12P
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search BERLIN		Date of completion of the search 22 February 2000	Examiner Fuchs, U
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

CLAIMS

1. A polypeptide having a kinase activity that is activated by transforming growth factor (TGF)- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5. 7
2. A polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5. 7
3. DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Ser at position 23 to Ser at position 579 set forth in SEQ ID NO: 5. 7
4. DNA according to claim 3 having a nucleotide sequence from T at position 249 to A at position 1919 set forth in SEQ ID NO: 5. 7
5. DNA encoding a polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide comprising an amino acid sequence from Met at position 1 to Ser at position 579 set forth in SEQ ID NO: 5. 7
6. DNA according to claim 5 having a nucleotide sequence from A at position 183 to A at position 1919 set forth in SEQ ID NO: 5. 7
7. A vector comprising DNA according to any of claims 3 to 6.
8. A host cell transformed with a vector comprising DNA according to any of claims 3 to 6.
9. A method for producing a polypeptide having a kinase activity that is activated by TGF- $\beta$ , which method comprises culturing a host cell transformed with a vector comprising DNA according to any of claims 3 to 6 and then recovering the product from the culture.
10. A polypeptide having a kinase activity that is activated by TGF- $\beta$ , said polypeptide being produced by the method according to claim 9.
11. A kinase that is activated by TGF- $\beta$ , said

4:25:01.99

kinase comprising an amino acid sequence from Ser at  
position 33 to Ser at position 179 set forth in SEQ ID  
NO: 5. *87/85/7A*

- 5 12. A fusion protein of a protein according to any  
of claims 1, 2, 10, and 11, and another protein.

- 33 -

ABSTRACT

5 A TGF- $\beta$ -activated kinase comprising an amino acid  
sequence from Met at position 1 to Ser at position 579 in  
the amino acid sequence as set forth set forth in SEQ ID  
NO: 5, and DNA encoding the kinase.